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ABSTRACT 
 
Growth monitoring is a fundamental part of preventive child health care since it aims for 
early detection of childhood illnesses. This screening process relies on important tools such 
as up-to-date growth reference curves, evidence-based screening cut-off values for 
abnormal growth, and accurate diagnostic procedures for early detection of growth 
disorders. The general aim of this thesis was to create new, evidence-based tools for 
auxological screening of growth disorders in children.  
Due to secular change in growth in children, growth references have to be up-dated 
periodically. The first part of this thesis consisted of the collection of contemporary 
auxological data from over 72,000 healthy children born between 1983 and 2009 which was 
then used to calculate new Finnish growth reference values. On average, Finnish children 
were found to be growing taller than children in the former Finnish growth reference (born 
1956 – 1973). The mean adult height of Finnish boys and girls had increased from 178.9 to 
180.7 cm (+1.8 cm), and 165.6 to 167.5 cm (+1.9 cm), respectively. 
In the second part of this thesis, screening of growth disorders in up-to-date national 
growth references was shown to outperform World Health Organization’s (WHO) recently 
published multiethnic growth curves. Screening cut-off value at specificity 99% detected 
55% of Turner syndrome (TS) girls when the new Finnish growth references were used as 
opposed to only a 20% detection rate with the WHO curves.  
In this study, evidence-based cut-off limits for attained height, weight and growth rate 
were developed, and these were validated against two target conditions: Turner syndrome 
(TS) and celiac disease (CD). Earlier detection of both conditions can be facilitated with 
systematic growth monitoring, and screening accuracy was found to be excellent [area 
under receiver operating characteristics curve (AUC ROC) = 0.99] for TS girls, and good 
(AUC ROC = 0.88 for girls and 0.84 for boys) for CD when several growth parameters were 
used simultaneously. 
The adoption of electronic health records provides an alternative to develop automated 
growth monitoring programs. In this study, the effectiveness of automated growth 
monitoring program was found to be distinctly better than its manually orientated 
counterpart in primary care. The automated strategy improved the detection rate of growth 
disorders by 6 – 7 -fold. It also identified numerous children with a growth disorder who 
would previously have been missed with the standard growth monitoring. 
Modern methods for growth monitoring in children are now ready for implementation 
in the healthcare system. Evidence-based growth monitoring program could be carried out 
accurately with these methods permitting the early detection of growth disorders in 
primary care. 
 
National Library of Medicine Classification: WS 103, WS 104, WS 141, WB 286, WX 175, QS 677, WD 175 
Medical Subject Headings: Body Height; Body Mass Index; Body Weight; Celiac Disease; Child; Electronic 
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TIIVISTELMÄ 
 
Kasvun seuranta on tärkeä osa lasten ehkäisevää terveydenhuoltoa. Sen tarkoituksena on 
tunnistaa aikaisessa vaiheessa kasvuun vaikuttavia sairauksia jo ennen muita sairauden 
oireita. Toimivan kasvun seurantajärjestelmän osat ovat ajantasaiset kasvukäyrät, 
tutkimusnäyttöön perustuvat kasvun seulontasäännöt ja hyvät diagnostiset menettelyt 
kasvusairauksien tunnistamiseksi. Tämän väitöskirjan tavoitteena oli uudistaa 
kasvusairauksien seulontaa Suomessa. 
 Lapsilla on ollut taipumus kasvaa vanhempiaan pidemmiksi aikuisiksi, minkä vuoksi 
kasvukäyrät tulee uudistaa säännöllisesti. Väitöskirjan ensimmäisessä osatyössä kerättiin 
yli 72 000 tervettä lasta (syntyneet 1983 – 2009) sisältävä kasvuaineisto, jonka avulla 
laadittiin uudet kasvukäyrät suomalaisille lapsille. Nykylasten havaittiin kasvavan 
keskimäärin aiempaa noin 40 vuotta vanhan kasvukäyräaineiston lapsia (syntyneet 1956 – 
1976) pidempinä. Poikien aikuispituus oli lisääntynyt 178.9 cm:stä 180.7 cm:iin (+1.8 cm) ja 
tyttöjen 165.6 cm:stä 167.5 cm:iin (+1.9 cm). 
Väitöskirjan toisessa osatyössä osoitettiin, että kasvuun vaikuttava sairaus voi jäädä 
tunnistamatta, jos käyttäisimme monikansallisia Maailman terveysjärjestön WHO:n -
kasvukäyriä ajantasaisten kansallisten kasvukäyrien tilalla Suomessa. Kansallisia 
kasvukäyriä käyttämällä Turnerin oireyhtymää sairastavista tytöistä 55 % jäi kiinni 
kasvuseulonnassa kahteen ikävuoteen mennessä, kun jatkotutkimuksiin poimittiin yksi 
prosentti terveistä lapsista. Vastaavasti vain 20 % tytöistä jäi kiinni WHO-käyrillä. 
Väitöskirjan kolmannessa ja neljännessä osatyössä laadittiin tutkimusnäyttöön 
perustuvat määrittelyt lasten poikkeavalle pituudelle, painolle ja kasvussa tapahtuville 
muutoksille. Turnerin oireyhtymää ja keliakiaa käytettiin tutkimuksissa mallisairauksina. 
Systemaattinen kasvuseulonta voi auttaa molempien sairauksien aikaisessa 
tunnistamisessa. Turnerin oireyhtymä oli mahdollista seuloa erinomaisella tarkkuudella 
[Receiver operating characteristic (ROC) -käyrän alle jäävä pinta-ala 0.99] ja keliakia hyvällä 
tarkkuudella (tytöt 0.88 ja pojat 0.84), kun kasvua seulotaan usealla kasvuseulasäännöllä 
yhtä aikaa. 
Sähköistä potilastietojärjestelmää on hyödynnetty vain vähän perusterveydenhuollon 
diagnostisena apuvälineenä. Väitöskirjan viidennessä osatyössä tutkittiin kasvun 
tietokoneavusteista seurantaa, mikä paransi selvästi kasvun seulonnan tarkkuutta 
perusterveydenhuollossa. Kasvuun vaikuttavat sairaudet oli mahdollista tunnistaa noin 
kuusi kertaa paremmin, ja usein selvästi aiemmin, kun verrattiin automatisoitua kasvun 
seurantajärjestelmää perinteiseen käsin tapahtuvaan laskentaan perustuvaan menetelmään. 
Uudet menetelmät lasten kasvun seurantaan terveydenhuollossa ovat nyt käytettävissä. 
Tutkimusnäyttöön perustuvat automatisoidut kasvun seurantamenetelmät parantavat 
seulonnan osuvuutta ja voivat aikaistaa kasvusairauksien tunnistamista 
perusterveydenhuollossa.  
 
Luokitus: WS 103, WS 104, WS 141, WB 286, WX 175, QS 677, WD 175 
Yleinen Suomalainen asiasanasto: kasvu; lapset; keliakia; kasvukäyrät; painoindeksi; pituuskasvu; seulonta; 
seuranta; tietokoneavusteisuus; Turnerin oireyhtymä 
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1 Introduction  
Assessment of growth is a fundamental component in preventive child health care. Growth 
monitoring is intended to detect childhood illnesses, ideally before any other signs or 
symptoms of the disease have appeared. Several important tools are used in this screening 
process e.g. growth reference curves depicting “normal growth” in the population, cut-off 
values defining abnormal growth, preferably as part of a systematic growth monitoring 
program (1). 
The Finnish growth reference values were based on auxological data of children born 
between the years 1956 and 1973 (2-4). However, contemporary children have had an 
ongoing tendency to grow taller than their parents (5-8), a phenomenon called “a positive 
secular change”, arising from changes in environmental factors which previously 
prevented full expression of the individual growth potential (9). Due to these secular trends 
in growth, the growth references need to be updated periodically (5). However, the 
magnitude of the positive secular change in height has decreased in Northern Europe in 
recent years (10), but studies from Finland are lacking.  
Due to the paramount importance of genetic factors in the regulation of growth and 
adult height (AH) (11-14), it is imperative that growth references are based on a population 
with the same ethnic and genetic backgrounds as present in the intended population (15-
19). In 2006, the World Health Organization (WHO) published multiethnic growth charts 
based on growth data of breastfed children younger than 5 years (20). Nevertheless, the 
basic idea inherent in the WHO’s growth references was the assumption that there was a 
similar growth pattern under optimal conditions in all humans irrespective of genetic 
background, a hypothesis criticized by several researchers (15,18,21,22). In these studies, 
the proportions of healthy children outside the ±2SDS of WHO references were different 
than expected. In addition, the feasibility of using multi-ethnic growth references for 
screening of growth disorders has never been tested.   
Body mass index (BMI) (weight/height², kg/m²) is considered as the best tool for 
monitoring the adiposity in both children and adults because of its independence on height, 
its correlation to body fat, and its ability to predict mortality (23-25). In contrast to the 
situation in most countries, BMI has not been used in adiposity assessment in children in 
Finland; instead, the percentage of the median weight-for-height has been used (2-4). Thus, 
there is a need for a Finnish BMI reference to monitor weight in children and adolescents.  
There is a wide variation in growth monitoring programs worldwide, and a substantial 
amount of health resources are allocated for childhood growth assessment (1,26,27). 
Despite the widespread traditions of growth monitoring, population-based cut-off values 
defining normal and abnormal growth  are virtually absent (1), and there is little 
information on how these parameters should be used in clinical practice (1,26,28-30). The 
adoption of electronic health records (EHR) presents an alternative to develop automated 
growth monitoring programs (31,32), but these alternatives have not been evaluated 
systematically. 
The primary aim of this study was to investigate and develop modern methods for use 
in growth monitoring program for children, starting from the assessment of growth and 
moving towards a well-established clinical practice to detect accurately abnormal growth in 
primary care. Thus, initially, up-to-date growth references were constructed for Finnish 
children and adjusted for secular trends in growth. Secondly, the new national growth 
curves were evaluated against multi-ethnic growth curves. Thirdly, cut-off values for 
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abnormal growth were established and validated in two target conditions: Turner 
syndrome (TS) and celiac disease (CD). Finally, the effectiveness of the novel computerized 
and automated growth monitoring program, in which screening algorithms were 
integrated into an EHR system, was compared to the manually operational approach in 
primary care. 
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2 Review of the literature 
2.1 HISTORICAL ASPECTS OF GROWTH MONITORING 
For more than a century, growth monitoring has been widely accepted as being an 
important component of preventive health care in children (33). Originally, the interest for 
assessing childhood growth was based on the concept that growth reflected general health 
and well-being as “a kind of mirror for health” (34). The divergence between normal and 
abnormal growth was already noted by the pioneers of auxology (34). Thus, the need for 
growth references that reflected normal growth was established already in the late 
nineteenth century, after these seminal observations of healthy and unhealthy growth in 
children.  
The history of growth studies begins with a description of the human growth written by 
the Greek poet Solon the Athenian in the sixth century BCE. He divided the human life into 
ten seven year periods, “hebdomas”, of which the first three described surprisingly 
accurately growth from infancy to adulthood. Nevertheless, the actual studies into human 
growth started in the eighteenth century, when the interest in human height came from the 
military who wished to recruit the tallest men who were considered to be strongest in 
battle. Christian Friedrich Jampbert was the first to publish the aggregated measurements 
of human growth in 1754 (35). Twenty years after Jambert’s thesis, the famous growth 
description by Philbert Guéneau de Montbeillard including the measurements of his son 
was published by the family friend, George-Louis Leclerc Buffon, in his fourth 
supplementary volume of Natural History in 1777 (36).  Montbeillard’s son had been 
measured at approximately semiannual intervals from birth to 18 years of age and this 
description provided excellent longitudinal data on the growth of an individual child. 
Buffon noticed the seasonal effects on the growth of this individual child, with a higher 
growth velocity during summer months. Even though Buffon analyzed intensively the 
Montbeillerd’s son’s growth, he did not apparently plot the height measurements against 
age as Richard Scammon (height against age) (37), and D’Arcy Thompson (height velocity 
against age) (38), did in their famous figures published in 1927 (Figure 1A) and 1942 (Figure 
1B).  
The next step in growth studies took place in the late eighteenth and early nineteenth 
centuries with large population-based datasets collected from army recruits in Europe. The 
earliest descriptions on secular trends in growth were made already in those years, 
including observation of the generally taller conscript from one generation to the next. An 
explanation for this phenomenon was not presented before the twentieth century. 
Apparently, the main purpose for these databases was to provide suitable equipment and 
clothes for the conscripts. At the same time, however, Carl Eugen used the longitudinal 
data of over 2,000 pupils of Carlschule School in Germany in 1770’s to argue that height 
velocity would reflect the individual health status better than attained height (33). This 
hypothesis was presented over one hundred years before the modern methods for growth 
monitoring had been devised. 
A large scale interest for height measurements increased in the nineteenth century, 
resulting in the fundamental finding that height was normally distributed. Adolphe 
Quetelet was one of the researchers with the observation of the “Gaussian errors around 
the mean” (39), thereafter called standard deviation (SD). In those times in the nineteenth 
century, the epidemiologists pointed out the association between hard work and poor 
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growth in children. These observations resulted in the proposal made by Charles Roberts as 
early as 1876 that too short and thin children should not work in factories (40).  
Francis Galton presented percentiles around the mean height in the late nineteenth 
century (41), and these curves were further developed by Henry Bowditch in the United 
States (42). He had then the revolutionary concept that “growth is guide to health” (43). 
Franz Boas established the charts with given SD scores (44), but it was not until 1922 that T. 
Brailsford Robertson constructed the novel method for growth monitoring, the first  growth 
charts with mean height and ±1 and ±2SD curves plotted against age (45). 
At the same time with the development of height monitoring methods, the early 
auxologists had noted the dependence between weight and height in children. Dumoutet 
was one of the first to publish harmonious weight tables with corresponding heights in 
1921 (46). After the first publications, weight-for-height became a widely accepted method 
to be used in weight assessment. However, the early auxologists observed that the weight-
for-height charts failed to account for the actual age of the child. Quetelet had devised and 
published an index for body composition as early as 1871, the body mass (kg) divided by 
the square of height (m2), better known as BMI (kg/m2) (47). Thus, BMI is also called 
Quatelet’s index. Nonetheless, it took until the end of the twentieth century before BMI-for-
age became established in the growth monitoring of children. 
In Finland, the first auxological studies were conducted at the turn of nineteenth and 
twentieth century. They followed the contemporary European example and gathered large 
sets of anthropological data from schools and conscripts from different parts of Finland 
(48). Fredrik Westerlund’s auxological database which included growth data of 131,697 
men from the military registers was one of these early Finnish growth surveys (49). 
 
 
Figure 1. Height-for-age (A) and height velocity-for-age (B) of Montbeillard’s son. Modified from 
A History of the Study of Human Growth (33).     
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He observed an association between AH and the mother tongue, but also regional 
differences in the AH. Mean AH in men was 168 cm, being the highest in Swedish-speaking 
men and in the Western part of Finland. In 1916, Finnish school teacher Ivar Wilskman 
performed growth studies among children aged 7 – 20 years (50); these are the oldest 
Finnish publications with serial height and weight measurements. He had continued 
Fredrik Westerlund’s intensive work in assessing regional and social differences in the 
heights of Finnish children. He also observed the positive secular trend when comparing 
his data with the earlier Finnish studies. In 1926, Hjalmar Söderström’s published the first 
Finnish growth charts entitled “harmonized weights” for Finnish children (51). These 
charts were based on measurements of over 5,800 pupils in the city of Helsinki. However, 
the first proper Finnish growth curves were published as a part of the doctoral thesis of 
Leena Bäckström-Järvinen only as late as 1964 (48). She conducted cross-sectional and semi-
longitudinal studies in different parts of Finland, and compared these with each other as 
well as with findings from other countries. As an appendix of her thesis, the height-for-age 
and weight-for-age curves for Finnish children were published. Nonetheless, growth curves 
were not implemented into the Finnish healthcare system before 1970’s (2), in spite of Arvo 
Ylppö’s remarkable pioneering work at well-baby clinics throughout the twentieth century. 
Eventually, increasing interest in growth monitoring in Finland was triggered after the 
publications of updated growth reference values by Ritva Sorva in 1984 (2). Her research 
group’s  work for cut-offs for screening of abnormal growth (3,4), was the first attempt 
anywhere in the world to develop an evidence-based growth monitoring program at the 
population level and remains exceptional even today (1,30). 
This brief history of growth monitoring was mainly based on the excellent overview on 
the evolution of study of human growth written by the late James M. Tanner (33). Tanner’s 
significance as one of the most important individuals in modern auxology is emphasized by 
his numerous publications on pediatric endocrinology, as well as his uncompromising 
work in the development of growth monitoring tools and thus for healthier children.   
2.2 HUMAN GROWTH 
Human growth is a complex process which is mainly genetically but also environmentally 
determined. The increase in body size due to the proliferation of tissues is regulated by 
several hormonal and environmental factors. Most of the growth in height occurs in the 
growth plates located between epiphyses and metaphyses of the long bones.  
2.2.1 Phases of growth 
Normal linear growth from conception to adulthood consists of four main phases: fetal, 
infancy, childhood and pubertal (ICP) growth (Figure 2) (52-55).  In reality, human growth 
is continuum of these periods that have specific regulators and controlling factors, and the 
attained height is considered as the sum of these phases.  
Fetal growth is dependent on maternal health and nutrition and linked with placental 
function. Birth size is genetically determined and its heritability is estimated at 
approximately 50% (56,57). The growth of the fetus is the most rapid in the second trimester 
when the growth rate can be as high as 2.5 cm per week (58). Fetal growth in favorable 
circumstances is regulated by fetal internal growth factors, however, the linear growth is 
very vulnerable to environmental factors present during this period. Any disturbances in 
fetal growth may not be corrected later in life. In the third trimester, uterine and placental 
factors tend to restrict the fetal growth, and the growth of fetus decelerates at the end of the 
normal pregnancy.  
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Figure 2. Infancy-childhood-puberty (ICP) growth model. Average growth patterns of Finnish 
male during infancy (1), childhood (2), puberty (3), and sum growth (1+2 & 2+3) are shown. 
Derived from Karlberg et al (52-55).   
 
 
Fetal growth failure may originate from congenital syndromes, chromosomal 
abnormalities or growth disorders (see Table 1, page 10). Alternatively, impaired growth 
may be attributable to placental factors, such as abnormal implantation and vascularization 
of placenta, or maternal reasons including malnutrition, hypertension, toxemia, gestational 
diabetes mellitus, medication or cigarette smoking during pregnancy. However, the 
etiology of intrauterine growth retardation cannot be often resolved. 
At birth, newborn infants are classified as small, appropriate, or large for gestational age 
(SGA, AGA, or LGA) according to their birth size. In general, the infant’s size at birth is an 
indicator of prenatal well-being, and thus its evaluation also provides a simple tool for 
estimating the risk of abnormal perinatal and long-term outcomes.  
After birth, the velocity of infant growth is rapid but also rapidly decelerating during the 
first year of life, so that it is approximately 25 cm/year (Figure 3A). The growth rate declines 
most markedly during the first 6 months of life, and thereafter this is followed by an 
average growth velocity of 10 to 15 cm/year until 2 years of age. Nutritional factors are 
important regulators of growth during infancy, but also hormonal regulation, e.g. mediated 
by growth hormone (GH) – insulin like growth factor 1 (IGF-1) -axis, thyroxine, sex steroids 
and glucocorticoids also have recognized key roles for infant growth. 
Weight is averagely gained rapidly after birth, reaching a maximum velocity of 13 
kg/year for boys and 11 kg/year for girls at the age of one month (Figure 3B). After the peak 
weight velocity, the gain in weight occurs more slowly until 8 months of age. In children 
from 1 to 2 years of age, the average weight gain velocity is approximately 2 to 3 kg/year. 
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Figure 3. Mean height (A) and weight (B) velocity in Finnish boys (solid lines) and girls (dashed 
lines) from birth to 2 years of age (I).   
 
Catch-up or catch-down growth, particularly in SGA and LGA children, is a 
characteristic of infant growth. During this period, growth is normally trajectorized into its 
own channel. For example, conditions that have transiently suppressed fetal growth (SGA) 
are assumed to accelerate growth rate (catch-up growth) after inhibiting factors are 
removed. Conversely, a condition that has led to LGA will often result in catch-down 
growth during infancy. The underlying mechanism behind this phenomenon is not clear, 
but recent experimental and clinical findings have found evidence for direct regulatory 
elements in growth plates with limited replicative capacity of chondrocytes (59,60), also 
called “growth plate senescence”. 
The second phase of postnatal growth according to the ICP-model, the childhood growth 
phase, begins from 6 to 9 months of age as an infancy-childhood growth spurt (61) that is a 
short acceleration of growth velocity during infancy, and a delay in this spurt is associated 
with short adult stature (62). The childhood growth predominates from 2 to 3 years of age, 
and continues until the onset of the pubertal growth spurt.  Nutrition becomes less 
important in the regulation of growth during childhood. Instead, the GH – IGF-1 -axis plays 
a key role in launching the infancy-childhood growth spurt (63,64). Growth impairment in 
many growth disorders during childhood is known to originate at least partially from a 
dysfunction of the GH-IGF-I axis. Nonetheless, GH has an important impact in childhood 
growth and thyroid hormone is also necessary for normal skeletal growth and maturation. 
It has dual role in bone growth. Longitudinal growth is promoted by direct action on the 
growth plate (65), and indirectly by regulation of the GH-IGF-I axis (66,67). 
During mid-childhood, growth may be accelerated due to the activation of the adrenal 
cortex and increased secretion of androgenic hormones, a phenomenon called adrenarche 
(68). Some of these children show signs of androgenic action including the presence of 
pubic hair, oily skin and adult-type sweating and body odor (69).  
The third phase of the ICP-model, the pubertal growth phase occurs on average 2 years 
earlier in girls than in boys  Characteristically, children undergo a short growth velocity 
deceleration before the onset of pubertal growth spurt that occurs on average 10 years of 
 
 
7
8 
 
 
age in girls and 12 years of age in boys (70). The mean age at peak height velocity is 12 
years in girls, and 14 years in boys, respectively (70). However, there has been a secular 
trend for earlier timing of pubertal growth phase in recent decades (70). On average, boys 
are only slightly taller than girls before puberty, and the majority of the difference in AH is 
a result of the later and more powerful pubertal growth spurt occurring in boys. The 
regulation of onset and the sustenance of pubertal growth require synergism between the 
GH-IGF-I -axis and sex steroids (71). The elevated production of estrogen (in girls) and 
androgen (in boys) accelerates growth, but also stimulates secretion of GH and IGF-I, which 
are essential for the development the effects of the sex steroids on the growth plate. Both, 
estrogens and androgens have key roles in the maturation of the growth plates, and 
eventually, estrogens will terminate the growth via fusion of the growth plates (72,73). 
 2.2.2 Secular trends in growth 
Over the past decades, growth surveys conducted in both the developed and developing 
countries have reported increases in the AH and earlier sexual maturation, a phenomenon 
termed a “positive secular change”(5). It is generally assumed that the positive secular 
change arises from environmental changes i.e. the lessening of those factors inhibiting full 
expression of the growth potential, e.g. inadequate nutrition and morbidity (9). The 
increase in the AH mirrors changes in the political and economic environment, and 
interestingly, a strong association exists between gross domestic product and secular 
change in growth (74).  
Since World War II, the greatest positive secular trend in mean adult height has been 
observed in Japan, 2.7 cm/decade (75), and smallest in Sweden and Norway, approximately 
0.3 cm/decade from 1950 to 1980 (76). The attained increase in mean adult height has 
determined to be achieved already during infancy and early childhood (5). However, the 
positive secular trend in height has not compressed height variations considered to be 
evidence of equal utilization of growth potential within populations in optimal living 
conditions. 
An earlier timing of pubertal growth spurt has been reported among Danish girls and 
boys (70). This phenomenon was associated with a higher weight before the onset of 
puberty (77); however, there was a downward trend in the age at which puberty was 
attained in both girls and boys, regardless of the BMI, suggesting that obesity is not solely 
responsible for this trend. In conjunction with the secular trends in pubertal growth, age at 
menarche has declined on average by nearly 2 years from 1920 to 1970 (78).  
The tendency towards taller children raises the question: are there any limits to this 
positive secular trend? Studies conducted among the Dutch who have been the tallest 
people in the world have shown a halt in the secular trend in the AH (79). The Dutch 
population is no longer growing any taller (79). The same finding has been also reported in 
Northern Europe (10). The general belief is that the secular increase in height continues 
until the genetic potential of the population is achieved. However, our current knowledge 
of the genetics of stature is insufficient to allow us to make any realistic estimation of the 
height potential of population. 
Overall, stature is strongly genetically determined in the general population, with 
heritability estimated at approximately 80% (80). To date, several genome-wide-association 
studies on the genes regulating stature have been published, mostly on Caucasian-based 
populations. These studies have identified more than 50 well replicated loci which are 
associated with stature (11-14). Because of the polygenic nature of stature, there are notable 
differences in the average height between populations with different genetic backgrounds 
(5-8,81). These can be explained by various mixtures of alleles associated either with short 
or tall stature. For the same polygenic reasons, the variation of height (i.e. SD of height) is 
similar between populations. 
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2.2.3 Growth disorders 
A child’s growth is considered an indicator of his or her general health and well-being, and 
failure to grow or failure to thrive is an early sign for poor health. Several conditions and 
illnesses could decelerate or accelerate linear growth. In addition, some growth disorders 
are typical for certain growth phases. An understanding of the regulatory factors involved 
in the different growth phases provides an opportunity to focus in appropriate clinical 
investigations of impaired growth. For example, wasting during infancy could be caused 
more likely from malnutrition, whereas failure to grow during childhood would be more 
likely to be attributable to growth hormone deficiency. 
Malnutrition is the main reason for growth failure in the developing countries, whereas 
congenital or acquired conditions are the most common reasons for growth impairment in 
the Western countries. Growth disorders causing short or tall stature are classified into 
primary, secondary, or idiopathic growth disorders (82). Short stature is often the only or 
the most obvious clinical sign of a growth disorder, such as in TS (28).  
There are some other common disorders leading for stunting, for example 
hypothyroidism, CD, growth hormone deficiency (GHD) and inflammatory bowel diseases. 
Growth disorders resulting in tall stature, however, are more infrequent than disorders 
leading to short stature, and include some common growth disorders, such as precocious 
puberty. The reasons for short or tall stature classified according to the European Society of 
Paediatric Endocrinology (ESPE) are presented in the Table 1 (82). 
TS is a congenital syndrome in girls that affects approximately 1/2,500 live births (83). 
The karyotype of TS girls shows a missing or partially missing female sex chromosome X. 
Various phenotypes exist, but the most common features in children, which affect over 90% 
of recognized patients, are short stature due to GHD or growth hormone resistance, and 
premature ovarian failure (28,83). Although, TS is a congenital syndrome it can present at 
almost any age from perinatal period to adulthood. Typically TS is diagnosed in three time 
windows postnatally (83,84): 1. neonatally by short stature or lymphedema, 2. during 
adolescence due to a lack of pubertal development, and 3. during adulthood as infertility. A 
diagnostic delay in girls with TS is common in the pediatric population (83,84). In addition, 
TS girls have an increased risk for congenital malformations and aortic coarctation, but also 
an increased mortality (83), and therefore early detection of TS is crucial. 
CD is an immune-mediated systemic disorder elicited by gluten and related prolamines, 
and the clinical pattern of childhood CD has changed from classical triad –failure to thrive, 
diarrhea and abdominal distention– and now includes a large variety of nonspecific signs 
and symptoms, including faltering linear growth, short stature or poor weight gain in 
children (85-89). CD is still underdiagnosed during childhood: based on serological studies, 
it has a prevalence of nearly 1:100 in Western populations (90), but only 10 to 20% of these 
patients are identified (85,90-94). Universal serological screening for CD in the child 
population would be one option to improve its detection rate, but the benefits and cost-
effectiveness of such screening remain controversial and it has not been recommended in 
the international consensus guidelines for the diagnosis of CD (85,93,94). 
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Table 1. Growth disorders in children. Modified from the ESPE classification for growth disorders 
(82). Some of the specific disorders are presented.  
 
Primary 
growth disorder 
 Secondary 
growth disorder 
 Idiopathic 
growth disorder 
Short stature     
Clinically defined syndromes  Malnutrition  Familial short stature 
Turner syndrome     
Williams syndrome     
Small for gestational age 
with failure of catch-up growth 
 Disorders in organ 
systems 
 Non-familial short stature 
  Cardiac disorders   
  Celiac disease    
  Crohn’s disease   
  Growth hormone 
deficiency 
  
  Other disorders of the 
growth hormone- IGF 
axis 
  
  Other endocrine disorders   
  Hypothyroidism   
  Metabolic disorders   
  Psychosocial   
  Iatrogenic   
Tall stature     
Clinically defined syndromes with 
sex chromosome abnormality 
including aneuploidy 
 Growth hormone 
overproduction 
 Familial tall stature 
Klinefelter     
Dysmorphic syndromes due to 
metabolic/connective tissue 
abnormality 
 Hyperinsulinism  Non-familial tall stature 
Marfan syndrome     
Other dysmorphic syndromes with 
symmetrical overgrowth 
 Familial (isolated) 
glucocorticoid deficiency 
  
Sotos syndrome     
Dysmorphic syndromes with 
partial/asymmetrical overgrowth 
 Hyperthyroidism   
  Conditions leading to tall 
stature in childhood, and 
normal or short stature in 
adulthood 
  
  Precocious puberty   
  Conditions leading to 
normal height in 
childhood, and tall stature 
in adulthood 
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2.3 GROWTH MONITORING 
Growth monitoring is a cheap and straight forward method to evaluate general health and 
well-being at the both individual and population level. In developed countries, it is 
intended to detect childhood illnesses, ideally before any other signs or symptoms of the 
disease have appeared (1,29,30). The fundamental components of a productive growth 
monitoring program are accurate methods and equipment for growth assessment including 
up-to-date growth references and preferably evidence-based tools for screening of 
abnormal growth, i.e. cut-off limits for abnormal growth (1,28,29). 
2.3.1 Assessment of growth 
In order to make a reliable assessment of growth is one needs to have standardized 
equipment and techniques so that the measurement can be reproduced at different times or 
places and by different people (95). Nevertheless, aims and circumstances of growth 
assessment vary between developing and developed countries from the itinerant nurses to 
the buildings of well-baby clinics, thus measuring tools have to be adjusted for the 
measuring environment. As a part of Multicenter Growth Reference Study conducted by 
WHO and completed in 2006 (20), extensive recommendations for measuring techniques 
and recordings were published (95), mainly for healthcare workers in the developing 
countries. In Finland, comparable recommendations have been issued by the National 
Institute of Health and Welfare (96). According to the WHO manual, children are weighed 
with the scales that can be tared for infants with the mothers on it instead of separate baby 
scales as are recommended in Finland. However, heights are measured identically in both 
recommendations with a length board in children less than 2 years of age, and a standing 
board for older children, respectively. The measuring equipment should be calibrated 
regularly (95). 
At each scheduled visit, length or height and weight are assessed using recommended 
standardized techniques and calibrated equipment. In infants up to age 20 to 24 months, 
the weight is measured without clothing on calibrated baby scales, and rounded to the 
nearest 0.005 kg. Length in the lying position or standing height is measured to the nearest 
0.1 cm, and standing weight is measured on calibrated step scales and rounded to nearest 
0.1 kg. The quality of growth data gathered at routine visits has been assessed in Finland, 
and it was reported that false measurements, typing errors, missing values, or duplicate 
recordings are rare (97). 
In Finland, approximately one million measurements are performed on children every 
year. Since the turn of the century, almost all measurements had been captured in the 
electronic patient management systems with specific programs for growth monitoring that 
have replaced the manual patient records. Growth data are gathered into EHR, in which 
longitudinal height, weight and head circumference data can be plotted on which are 
displayed on the computer screen growth curves. Additional data, e.g. birth size, 
gestational age, pubertal stage and parental heights, are also included in the EHRs. 
2.3.2 Growth references 
The main aim of the use of a growth reference is to answer the question: “Is this child 
growing normally?” Thus, growth curves should be constructed on the auxological data of 
the reference population, from which abnormally growing patients have been excluded. It 
is important to understand the conceptual distinction between ‘reference’ and ´standard´. 
The reference is only the descriptive for variation in the population as a whole, while a 
standard defines the variation that is assumed to be normal and healthy under optimal 
conditions. However, the distinction between “growth reference” and “growth standard” is 
often indistinct. Cleaning procedures for initial data are intended to end up with normative 
(standard) growth as accurately as possible, but healthy and optimal growth might be 
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difficult to delineate. A more or less intensive cleaning process for reference data might 
result in distortion of the final data. In fact, this is the case with the weight reference. 
Healthy weight gain is almost impossible to define. Thus, children with growth disorders 
are excluded from weight reference population only. There are widely accepted methods 
for exclusions for height reference population to reflect optimal, healthy linear growth are 
(6,8,20,81): 
 
1. Children with growth disorder or medication possible affecting growth 
2. Premature children with gestational age less than 37 weeks 
3. Low or unknown birth weight (under 2500g) 
4. Extreme height-for-age (outside ±4SD) 
5. Underweight or obese children 
 
The use of growth reference curves is an essential component of the effective growth 
monitoring. These curves describe the variation of auxological measurements in the child 
population. Growth references are used for health assessment at both the individual level 
i.e. for identifying an individual as being in need of special consideration, and to assess 
individual response to intervention; or at the population level assessing prevalence, 
evaluating trends, detecting subpopulations at risk, and in monitoring the impact of 
interventions (20,98). 
The variation of growth in the reference population is expressed in growth curves 
between -2 and +2 SD, or the corresponding curves for 2.3 and 97.7 percentiles (Figure 4), 
which include observations of approximately 95.4 percent of all persons of the reference 
population. Traditionally, height growth is displayed against age (height-for-age), and 
weight as a function of height (weight-for-height or BMI-for-age), due to fact that body 
mass depends on both lean mass (mostly height growth) and fat mass. 
Data collection for growth references may be carried out cross-sectionally, longitudinally 
or by a mixed-longitudinal design; the method being chosen mainly depends on how the 
data is to be interpreted (98). Generally, growth curves are based on cross-sectional studies, 
in which children of different ages are measured once at the same point of time. These 
growth surveys are relatively easy to perform, and data can be analyzed immediately.  
Cross-sectional growth references, however, do not provide accurate information on 
growth rate and therefore these curves are not suitable for longitudinal growth monitoring. 
Instead, this kind of data demands a longitudinal design including repeated measurements 
in the same children. Curves base on longitudinal data can be delineated with a smaller 
sample size than cross-sectional curves. Longitudinal studies, however, are more laborious 
to carry out because the same individual has to be measured often and that increases the 
risk for drop-outs and data is more difficult to manage. Moreover, should the time-range 
between the start and the end of the data collection be a long time, then the reference may 
have become already outdated by the time of finishing data collection due to a secular 
change in the population. The mixed-longitudinal design is a compromise from both cross-
sectional and longitudinal studies. Individuals in the reference population are measured 
more than once, but not across the entire age range, allowing for a combination of the 
benefits of the both data collection methods. Traditional growth references are distance-
type growth curves that could be constructed with a cross-sectional sample. Distance 
references are used in comparison of attained growth between two populations, 
comparison of attained growth of the same population at different occasions, and one can 
detect an individual’s impaired growth using a single observation located in the extreme 
percentiles (98). However, longitudinal patterns of growth cannot be assessed by distance 
growth curves. If one wishes to study growth velocity, a reference constructed from 
longitudinal collection of data is needed.   
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Figure 4. Finnish growth curves for mean height (solid lines) ± 1 & 2 SD (dashed lines) for boys 
(A) and girls (B) published in 1986 (2-4). 
Recent growth studies, for example Dutch (6), Norwegian (8), and WHO Multicentre 
Growth Reference Study (20), have been invariably based on a mixed longitudinal design. 
In addition, as a part of the WHO’s project the statistical methods were evaluated to 
determine the best method for curve fitting of data from a mixed-longitudinal setting. This 
intensive work terminated in an application for the comprehensive method of smoothing 
for growth curves, known as the LMS-method (L for skewness, M for median and S for 
coefficient of variation) by Cole and Green (99,100), the Generalized Additive Models for 
Location, Scale and Shape (GAMLSS) (101), in which it is assumed that age-conditional 
distribution is normal after applying a Box-Cox type transformation. The major advantage 
of the method is that after transformation of the data that are originally not distributed 
normally, these can  be managed as if they were normally distributed, and the values for 
attained growth can be transformed to  SD scores (SDS).   
Longitudinal growth data collected in a mixed-longitudinal setting can be utilized for 
generating conditional references. However, the interpretation of the growth rate over time 
is affected by the regression to mean (102) that is a statistical phenomenon encountered 
with repeated measurements in a single individual. A child growing in an extreme 
percentile is expected to be less extreme in the next observation. The conditional reference 
proposed by Cole (103), takes this kind of regression towards the mean into account. 
The Finnish growth references were launched in 1986 and are based on height and 
weight measurements of 2,305 children born between 1954 and 1972 (2-4). In Finland, 
height growth is interpreted as SDS against age (2), therefore growth curves for mean 
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height ±2SD are drawn as horizontal lines (Figure 5). In addition, in contrast to most 
Western countries, weight is assessed as a percentage of the median weight-for-height, 
instead of BMI-for-age percentiles (2-4,104). Data correlating BMI and weight-for-
length/height in childhood are scarce. A single study from the United States revealed a 
poor correlation, indicating that these two endpoints are not interchangeable (105). 
Growth curves have to be renewed regularly due to secular changes. Theoretically a 
secular shift up to +0.4 SDS in the average height would result in a 3.4% reduction in 
specificity and up to a 32.6% reduction in sensitivity in the  screening of short and tall 
stature with cut-off points at ±2 SD.  
In 2006, the WHO published multiethnic growth charts for breastfed children younger 
than 5 years (20). Those WHO curves are intended to show how children grow under 
optimal conditions irrespective their genetic background. Originally, the rationale for the 
construction of the multiethnic WHO references stemmed from an earlier study that 
reported very similar growth patterns in infants and children from diverse ethnic 
backgrounds when their physiological needs are met and their environment can support 
their healthy development (106,107). Nevertheless, in recent studies from Norway and 
Belgium, proportions of the healthy children outside the ±2 SDs of WHO standards were 
different than expected (15).  
 
 
 
 
Figure 5. Height-for-age growth reference of Finnish boys aged 1 to 20 years expressed as SD-
values. Growth curve is plotted by using height isometers (70 – 210). Derived from Sorva et al 
(2). 
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Moreover, children in Hong Kong living under optimal conditions (same inclusion 
criteria as used by WHO), on average were shorter than the mean of the multi-ethnic 
growth reference (18). Data collection of WHO growth references has also been criticized 
due to selective drop-out (108). Thus height assessment in children growing at the outer 
percentiles with potential morbidity may be flawed if one uses the WHO standards. 
However, WHO’s growth curves are applicable at least in countries without national 
growth references (20). 
In the recent decades, western countries have been alarmed by an epidemic of obesity 
(109-111). In Finland, the prevalence of overweight adolescents has almost doubled in the 
past two decades (112,113). Overweight and obesity often persist into adulthood and are 
recognized as risk factors for chronic diseases such as cardiovascular disease and type 2 
diabetes (114-117). BMI (weight/height², kg/m²) is considered the best tool for monitoring 
the epidemiology of overweight and obesity in both children and adults because of its 
independence of height, correlation to body fat, and ability to predict mortality (23,24,118-
121). The normal body composition changes from infancy to adulthood. Thus, the reference 
values for BMI are age- and sex-specific. However, detailed knowledge of BMI thresholds 
related to morbidity in childhood is still lacking (116,121-123). Nonetheless, there are no 
BMI-for-age growth curves for Finnish children implemented in electronic health records. 
2.3.3 Methods for auxological screening of growth disorders 
The main aim of growth monitoring is identification of treatable disorders in an apparently 
normal child. Early diagnosis helps to minimize the impact of the underlying health 
condition and to optimize final AH. Thus, growth monitoring meets the criteria as a 
screening program (124,125) that can identify not only one disorder, but several treatable 
causes of abnormal growth that might have been overlooked or remained undetected in 
current practice. In undeveloped and developing countries, weight screening with recent 
WHO multi-ethnic growth references has been reported to be feasible tool for the detection 
of malnutrition (126-128), and for monitoring children at risk of pre-term death (129,130).  
In the developed countries, however, the main focus of growth monitoring programs is in 
the early detection of disorders affecting linear growth.  
Growth monitoring is believed to be efficient if growth impairment is the only or the first 
sign of a growth disorder, and there are no other clinically obvious symptoms that might be 
present. TS and GHD are prevalent conditions that are responsible for failure to grow, and 
which might be identified accurately via growth monitoring (30). There are also other 
disorders that may be detected for example CD, hypothyroidism and precocious puberty.  
The efficacy and accuracy of growth monitoring as a screening test are assessed via 
specificity and sensitivity (Table 2). Specificity is the proportion of children without a 
growth disorder who test negative, and sensitivity is the proportion of children with a 
growth disorder who test positive. The calculations of these screening characteristics are 
based on true negative and false positive rate for specificity, and true positive and false 
negative rate for sensitivity (see Table 2). The diagnostic accuracy of growth monitoring is 
always a trade-off between sensitivity and specificity. Growth monitoring cut-offs are 
intended to detect as many abnormally growing children as possible (high sensitivity) 
without producing too many unnecessary referrals or further investigations (high 
specificity). However, three important differences between growth monitoring and other 
screening programs have been described by Stef van Buuren and Paula von Dommelen 
(125). First, an intervention attributable to impaired growth is usually initiated when the 
patient displays other clinical symptoms, whereas the conventional screening program is 
only dependent on the result of the test. Second, growth monitoring is not only aimed at 
identifying a single disorder, unlike traditional screening programs. Third, children growth 
monitoring could be performed with a time dimension, while a population is tested at one 
moment or via several tests at a given age (125). 
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Table 2. Screening specificity and sensitivity 
Screening disorder Screening test positive Screening test negative 
Yes True positive (a) False negative (b) 
No False positive (c) True negative (d) 
Specificity = d / (c + d) 
Sensitivity = a / (a + b) 
Growth monitoring is intended to detect childhood illnesses (see Table 1), ideally before 
any other signs or symptoms of the disease have appeared. Screening specificity for a single 
measurement is defined by growth references, but the sensitivity of growth monitoring 
program will still remain unresolved, if it is not validated with target conditions. 
Conditions which are important to detect early, and which cannot easily be recognized 
since there are few or even the complete absence of presenting signs justify population-
based screening of growth disorders in general (30). The assessment of diagnostic accuracy 
for these specific disorders is essential in this validation process of growth monitoring 
programs. 
Evidence-based cut-off values for abnormal growth are needed if growth monitoring is 
to be considered as a reliable screening program (124,125). Several auxological variables can 
be utilized for screening process (125), but the simplest and most widely used method is 
fixed percentile or SD cut-off for the growth reference (see Table 3). This inexpensive and 
easily carried-out method can be reasonably performed in a cross-sectional setting. In 
addition, screening specificity is pre-designated, as long as growth curves have been 
adjusted for the secular trend, and are representative for the given population. For 
example, a cut-off value 0.5th percentile for short stature corresponds to the screening 
specificity of 99.5%. However, longitudinal growth data of the monitored children cannot 
be utilized in fixed percentile cut-off values. 
Abnormal growth rate by age can be screened by using conditional growth references. 
The variation of the growth rate over time is based on the fact that the distribution of the 
change in height or weight SDSs at a fixed age interval is normally distributed. Thus, 
screening specificity for growth rate is also pre-defined in the percentile or SD cut-off value. 
However, longitudinal growth assessment is sensitive for measurement errors, and several 
calculations between two time points might be laborious if they need to be done manually.  
Height varies within a given population, mostly due to familial (which are also mostly 
genetic) factors.  These can be taken into account by using an auxological variable called the 
target height (TH). TH represents an interesting approach for growth monitoring since it is 
believed to improve accuracy of growth monitoring, because the height variation in TH is 
narrower than the variation in height itself (131). Nevertheless, screening with TH method 
is dependent on both parental heights. Several methods have been proposed for calculating 
TH (132-134), but their accuracy in the context of growth monitoring has never been tested.  
The most widely used adult cut-off values for weight are a BMI value of 25 kg/m2 for 
overweight and 30 kg/m2 for obesity, these values have also been related to increased health 
risks (110). An International Obesity Task Force (IOTF) expert panel proposed that BMI-for-
age percentile curves passing through adult values of 25 kg/m2 and 30 kg/m2 could be used 
for defining childhood overweight and obesity, respectively (110,135). Multi-national 
curves were subsequently constructed by Cole et al. with grades of 3, 2, and 1 thinness in 
children defined as BMI-for-age percentiles passing through adult values of 16, 17, and 18.5 
kg/m2 (136), respectively. 
2.3.4 Growth monitoring programs 
Growth monitoring practices have been adopted worldwide (27), but are hardly ever based 
on consensus statements or evidence-based screening cut-off values (1,137,138), and 
therefore the effectiveness of routine growth monitoring is considered as having been 
insufficiently explored (1,30). There are currently 12 published growth monitoring studies 
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for height using diagnostic approaches (29,32,139-148). An overview of these publications is 
presented in Table 3.  Most of the studies were based on a single measurement at a certain 
age (32,139-145,147,148), and 11 of 12 studies utilized simple cut-off values for abnormal 
growth (percentiles or SDS) that, however, have not been tested in clinical practice. In 
addition, only three studies estimated the growth rate (29,142,146). Furthermore, 
longitudinal growth data was not utilized in any of these studies.   
The detection rates for growth disorders were reported in nine studies, in which one 
growth disorder could be detected per 1000 measured children. However, only the one 
study of Grote et al (29) used evidence-based growth monitoring cut-offs in the evaluation 
of clinical effectiveness and diagnostic accuracy of a growth monitoring program for their 
target conditions (TS, GHD, cystic fibrosis and CD). Thus, in the systematic review 
published by Craig et al it was assessed as the only relevant study that provided a referral 
strategy for short stature (1). The review concluded that appropriate referral strategies for 
growth monitoring had still been insufficiently explored.  
An effective growth monitoring program should contain the following key components 
(1,26,30): 
 
1. Measurements are taken with standardized the methods by the trained health care 
professionals  
2. It uses up-to-date  and appropriate growth reference (149) 
3. Well-established cut-offs for abnormal growth are used 
4. It facilitates early detection of disorder(s) affecting  growth 
5. It results into improved prognosis through earlier detection of disorders 
 
According to the literature search, there are clear differences in the published growth 
monitoring programs (2-4,29,30). In the UK, a single measurement of less than 0.4th 
percentile at school entry as a screening program for abnormal growth is used (30). This 
cut-off value is based on the single study of Voss et al (148), and has never been validated 
under target conditions. The unused potential of the longitudinal growth data is a clear 
disadvantage in the UK system. 
Finnish primary care represents a unique growth monitoring program (2-4,104). The 
entire child population is covered by a free-of-charge national health monitoring program, 
which is enshrined into the law (150). Primary care nurses are trained in child health care 
and health prevention, and their duties include the assessment of health and development 
at scheduled visits including standardized weight and height measurements. Finnish 
children make regular visits to child health clinics at the ages of 1 to 4 weeks; 4 to 6 weeks; 
at 2, 3, 4, 5, 6, 8, 10, 12, 18, and 24 months, and then at 3, 4, 5, and 6 years of age (96). After 
six years of age, children and adolescents visit the school health care annually. In addition, 
children may make extra visits if any distinct health concerns are suspected.  
Monitoring strategy includes manual growth evaluation with two screening algorithms, 
for attained height and growth rate that have been used in Finland since 1989 (Table 4). 
Screening cut-offs are set to a specificity of 99% corresponding to the 0.5th percentile for 
short stature, and 99.5th percentile for tall stature, respectively. If the primary care nurse 
considers the growth to be abnormal, then she/he consults the primary care physician who 
performs an assessment or baseline investigations and may then refer the child to 
secondary care.  
The Finnish growth monitoring program is extensive. Furthermore, longitudinal growth 
data is utilized, and screening cut-off values cover also tall stature. However, in clinical 
practice, these screening rules are considered as too complex and difficult to utilize. Despite 
the fact that the UK and Finland have long traditions of growth monitoring, the cut-off 
values have not been validated with evidence-based methods in either country. 
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Table 4. Finnish growth monitoring algorithms for abnormal growth (2-4,104). 
 
I Algorithm Cut-offs for height-for-age 
Age < 1 year Length within 2.3 SD from the population mean  
$JH 1 year Length/height within 2.3 SD from the target height (calculated from 
parental heights) or within 2.7 SD from the population mean (if target 
height not known) 
 
II Algorithm Cut-offs for growth rate (change in height SDS) 
 Age (years) 
Preceding time 
(years) 0.25 0.5 0.75 1 1.25 1.5 1.75 2.0 
   
0.25 1.7 1.1 0.9 0.9 0.8 0.7 0.6 0.6    
0.50  2.1 1.6 1.5 1.4 1.3 1.2 1.0    
0.75    2.3 1.9 1.7 1.6 1.5    
 2 3 4 5 6 7 8 9 10 11 12 
1 1.5 1.4 1.2 0.9 0.9 0.9 0.7 0.6 0.6 0.7 0.7 
3   1.8 1.5 1.2 1.1 0.9 0.9 0.9 1.0 1.1 
5     1.9 1.7 1.4 1.3 1.3 1.3 1.3 
 
In the Netherlands, screening guidelines for short stature were recently published for 
Dutch children (29). Details of this programme are presented in Floor Grote’s thesis which 
was published in 2007. In her summary, she proposed guidelines for developing a growth 
monitoring program organized according to a step-by-step flow diagram for age, attained 
height and growth rate (Figure 6). Growth screening (referral criteria) cut-off for children 
more than 3 years of age were very short stature (HSDS < -2.5 SD) or short stature (HSDS < -
2 SD) with dimorphic features or small for gestational age. If none the above criteria were 
not met, however, child should be referred if height SDS deviation from TH was > 2 SD or 
the growth rate was < -1 SD. For children less than 3 years of age, the referral criteria were 
extreme short stature < -3 SD or repeated very short stature < -2.5 SD. The clear advantage 
was that the guidelines for short stature were based on validation studies performed for a 
few target conditions (TS, GHD, CD and cystic fibrosis) resulting in good sensitivity 
(varying from 77 to 86%) with acceptable specificity (98 – 98.5%) (29). However, growth 
syndromes for tall stature were not incorporated into these guidelines. 
2.3.5 Computer assisted growth monitoring program 
Irrespective of the country, a substantial amount of health resources are invested in 
childhood growth monitoring. Nonetheless, diseases affecting growth are still diagnosed 
late with possible detrimental effects on long-term health-related outcomes (1,84,151). Thus, 
better strategies for childhood growth monitoring are needed. 
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Figure 6. Flow diagram of Dutch criteria for referral of children with short stature. Derived from 
Grote et al. (29).  
Abbrevations: HSDS, Height-for-age standard deviation score; SGA, Small for gestational age; 
TH SDS, Target height standard deviation score 
 
 
 
EHR are widely used in health care throughout Europe (27). Recently published study 
on growth monitoring practice showed that on average 61% of European paediatricians are 
utilizing some kind of computer software with which to monitor growth (27).  Every fifth 
was using a simple screening algorithm for abnormal growth, although, those were not 
implemented into EHR. It is noteworthy that none of the respondents were utilizing any of 
the published growth monitoring algorithms. 
The adoption of EHRs represents an opportunity to develop growth monitoring. Several 
steps of growth monitoring are suitable for automation, e.g. automated plotting of growth 
charts, computerized screening algorithms for abnormal growth, and automated flagging of 
abnormal screening results. In addition, automatic consultation services could be 
constructed between primary and secondary (or tertiary) care if abnormal growth is 
detected. It seems that the German program described by Keller et al (32) and Kiess et al 
(31) is the only computer-based growth monitoring system, in which routine height 
measurements are gathered on an ongoing basis in more than 100 participating paediatric 
practices throughout a wide area of Germany. Children with heights above the 97th 
percentile or below the 3rd percentile on the German synthetic normal curve were 
highlighted to the relevant practice, and children were referred for specialist investigation if 
this was deemed necessary. Nevertheless, automated growth monitoring strategies (AM) 
have not been evaluated systematically. It is not known whether an AM integrated in EHR 
in primary care will perform better than a standard growth monitoring (SM) strategy based 
on the primary care providers’ interpretation of the child’s growth pattern. 
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Referral 
HSDS < -2 SD 
Repeated 
HSDS < -2.5 SD 
HSDS < -3 SD 
HSDS < -2.5 SD 
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Dysmorphic 
features 
Referral 
HSDS – TH SDS < -2 SD 
N
o further investigations 
Growth rate < -1SD 
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3 Aims of the study 
The aims of this study were: 
 
x to evaluate secular trends in growth occurring in Finland from 1950s 
x to construct new population-based growth references  
x to compare the performance of the population-based new growth reference with 
the multi-ethnic WHO growth reference in detecting abnormal growth, using  TS 
as a model of a growth disorder 
x to establish evidence-based screening cut-offs for detection of abnormal growth, 
and test the performance of these cutoffs using TS and DC as models of growth 
disorders  
x to assess the effectiveness of a computer-assisted growth monitoring program in 
primary health care. 
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4 Material and methods 
4.1 GROWTH REFERENCES 
Data for constructing the new growth references were collected from providers of public 
primary care in the Southern city of Espoo, Finland’s second largest city with a population 
of 241,600 inhabitants. The majority of the population (94.4%) is of Finnish origin which 
mirrors the whole of Finland (97.3%). Historically, the population has grown by over 10-
fold over the past 50 years with a significant net migration from all parts of Finland (152). 
The Finnish social security system provides regular, free-of-charge visits to public 
primary care child health clinics and school health care to permanent residents of Finland 
regardless of social status or income level (150). Primary care nurses in Finland are specially 
trained in child health care and health prevention and their duties include assessment of 
health and development at these scheduled visits including standardized weight and 
height measurements. Children in Espoo make regular visits to child health clinics at the 
ages of 1 to 2 weeks; 3 to 6 weeks; 6 to 8 weeks; at 2, 3, 4, 5, 6, 8, 10, 12, 18, and 24 months, 
and then at least annually up to 18 years of age. Children may have also extra visits if any 
special health concerns are suspected. 
Length/height and weight are measured using standardized techniques and with 
calibrated equipment. In infants up to age 20 to 24 months, length is measured to the 
nearest 0.1 cm in a fully extended supine position with heels in contact with a baseboard. 
The infants are weighed without clothing on calibrated baby scales, and the weight is 
rounded to the nearest 0.005 kg. From the age of 24 months, standing height is measured to 
the nearest 0.1 cm using standardized stadiometers and standing weight is measured with 
calibrated mechanical or electronic step-scales being rounded to the nearest 0.1 kg. Since 
2003, all measurements in the Espoo area had been entered into an EHR (Effica, Tieto Ltd, 
Finland). The weight and length measured in the birth hospital, as well as data on 
premature birth have also been recorded in the Effica program at the first visit to the child 
health clinic. 
4.1.1. Data collection, and database cleaning 
For the weight-for-length/height and BMI-for-age references, were the auxological data 
from Espoo recorded in the Effica system between 1 January 2003 and 12 May 2009 used. 
All potentially false measurements, typing errors, missing values, or duplicate recordings 
were corrected or excluded. The initial database for weight-for-length/height and BMI-for-
age reference contained 561,392 length/height and weight measurements from 75,810 
subjects aged 0 to 20 years. Data cleaning occurred in two phases (Figure 7).  
First, the primary health care nurses retrospectively evaluated the eligibility of each 
subject for the new growth reference. These nurses had been specifically trained by a 
pediatric endocrinologist (L.D.) to exclude medical diagnoses or medications that could 
have possibly interfered with growth.  Second, any potential bias as a result of repeatedly 
measuring the same subject was eliminated by grouping the measurements into 29 time 
slots according to the official visiting schedule in the Espoo child health clinics and school 
health care. Only one measurement per child per time slot was selected (the closest visit to 
the correct visiting age).  The weight-for-length/height and BMI-for-age references were 
constructed from the resulting mixed cross-sectional and longitudinal database comprised 
of 73,459 subjects aged 0 to 20 years (35,890 girls and 37,569 boys) with 428,326 
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length/height and weight measurements. The subjects were born between 9 May 1983 and 5 
May 2009.  
For the length/height-for-age reference, the initial database was comprised of subjects 
from the weight reference population who had made at least one scheduled visit between 
10 March 2008 and 9 March 2009 (40,655 subjects/285,488 measurements) (Figure 8). The 
past and present growth data of each measured individual was evaluated systematically by 
automated screening according to the existing Finnish growth screening rules (see Table 3) 
(3,4). Children with faltering growth curves identified by the automated screening method 
were referred to a pediatric endocrinologist who excluded children with suspected 
abnormal growth curves from the database (see Figure 12). Male data were supplemented 
by 200 measurements of  healthy, consecutive army conscripts aged 18 to 20 years from the 
Garrison of Santahamina (Helsinki, Finland) and fulfilling the above general inclusion 
criteria for the database. Military service is compulsory for all healthy young male (aged 
over 18 years) adults in Finland, and the subjects chosen for the present study originated 
from the same area of Southern Finland as the whole study population. 
Furthermore, subjects (and all their measurements) with conditions possibly affecting 
growth or significantly differing from the average (i.e., those with prematurity, low or 
unknown birth weight, height below -4 SD or over +4 SD, and underweight or obesity; 
(Figure 8) were excluded from the height reference database. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Data cleaning procedure for the weight-for-height and BMI-for-age reference 
database. 
INITIAL DATABASE FOR WEIGHT-FOR-HEIGHT AND BMI-FOR-AGE REFERENCE 
76,010 subjects 
561,592 measurements 
 Auxological data recorded between Jan 2003 and May 2009 plus 200 
measurements from healthy male conscripts aged 18 – 20 years 
73,659 subjects 
532,132 measurements 
Exclusion of subjects with medical diagnoses or 
medications possibly interfering with growth 
 2,351 subjects 
 29,460 measurements 
Exclusion of repeated measurements from the 
same subject inside any of the 29 time slots 
(one slot for every scheduled visiting time) 
 103,606 measurements 
FINAL DATABASE FOR WEIGHT-FOR-HEIGHT AND BMI-FOR-AGE REFERENCE 
73,659 subjects (96.9% of the initial database) 
428,526 measurements (76.3% of the initial database) 
 Aged 0 – 20 years 
 born between 9 May 1983 and 5 May 2009 
 1 – 17 measurements per subject 
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Figure 8. Data cleaning procedure for the height reference database.  
aScreening cut-off values: height SDS deviation outside ±2.7SD from the mean, or outside ± 
2.3 SD from the target height, or change in height SD in the preceding 1, 3, or 5 years 
exceeding the age-specific cut-off values;  
bUnderweight: weight-for-height below -15 % of the median in height of 50–129 cm, below -
20% in height of 130–159 cm and below -25% in height of 160–180 cm; 
cObesity: weight-for-height above 20% or 40% of the median weight-for-height in children less 
than 7 years or 7 years or more, respectively (3,4). 
 
 
 
 
 
 
INITIAL DATABASE FOR HEIGHT-FOR-AGE REFERENCE 
40,655 subjects 
285,488 measurements 
 Subjects of the final weight reference database (see Figure 6) who had at least one 
scheduled visit between 10 March 2008 and 9 March 2009. Growth was monitored 
automatically according to the screening rules* 
40,398 subjects 
283,694 measurements 
Exclusion of subjects with suspected abnormal growth 
(growth screen alerta AND evaluation by a endocrinologist) 
 2257 subjects 
 1,794 measurements 
Exclusion of subjects with any of the following 
 prematurity (< 37th gestational week) (604 subjects) 
 unknown birth weight (11,688) 
 low (< 2.5 kg) birth weight (295) 
 height outside ± 4SD) (85) 
 underweightb (2,221)  
 obesityc (2,740) 
 13,762 subjects and 101,909 measurements 
FINAL DATABASE FOR HEIGHT-FOR-AGE REFERENCE 
26,636 subjects (65.5% of the initial database) 
181,785 measurements (63.7% of the initial database) 
 Aged 0 – 20 years 
 born between 18 Dec 1983 and 23 Dec 2008 
 1 – 17 measurements per subject 
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The final database for the length/height-for-age reference included mixed cross-sectional 
and longitudinal data, including 181,785 length/height and weight measurements of 26,636 
full-term, healthy subjects (12,895 girls, 13,741 boys) born between 18 December 1983 and 
23 December 2008. The number of measurements per subject varied from 1 to 17.  
4.1.2 Curve construction and statistical analysis  
In the construction of growth references (length/height-for-age, weight-for-length/height, 
BMI-for-age), the distribution of response variables and smoothing techniques of the 
distribution parameter curves over the explanatory variables were chosen by closely 
following the guidelines provided by the WHO (20). GAMLSS were used, choosing the 
distribution of a response variable from the flexible Box-Cox Power Exponential (BCPE) 
distribution family and using cubic splines as a smoothing technique (101). The BCPE 
distribution can be described in terms of four parameters: M for median, S for coefficient of 
variation, L for Box-Cox transformation power, and T which is a parameter related to 
kurtosis. 
The R statistical software (GAMLSS package) was used in the analysis (101). First, 
optimal power transformation was calculated by non-linear regression for the explanatory 
variable in relation to the response variable as it was found to improve goodness of fit. 
Second, optimal degrees of freedom for parameter curves were defined using the optimal 
function and the Akaike Information Criteria (AIC), the Generalized AIC (GAIC), and the 
Bayes Information Criteria (BIC) (which have penalty h of 2, 3 and log(n) in the formula -
2L-hp, where L is the maximized likelihood, p is the number of parameters in the model, 
and n is the number of observations). Modeling was started from the normal distribution 
(BCPE with L=1 and T=2) and extended to the Box-Cox normal (BCPE with T = 2, also called 
LMS method of distribution where L is the skewness, M is the median, and S is the 
coefficient of variation) or full BCPE, if needed. In choosing the “best” model, the main 
emphasis was settled to the plot of fitted percentiles with observed percentiles.  Usually, 
the BIC information criterion was found as being more applicable than AIC or GAIC, 
possibly due to the large numbers of observations. 
Finally, a normal distribution assumption for height was obtained in the height-for-age 
analysis. Growth curves for height-for-age were depicted as the mean (M) and mean plus 
or minus two standard deviations which covered the 2.3th, 50th and 97.7th percentiles. 
Response variables (BMI and weight) assumed as being a normal Box-Cox distribution. 
BMI, in the BMI-for-age analysis, was described in terms of the 3rd, 10th, 50th, 90th, and 97th 
percentiles and the percentiles passing through BMI values of 16, 17, 18.5, 25, and 30 at age 
18 years; the widespread method by Cole to define various grade of thinness, overweight 
and obesity for Finnish children (135,136). Median (the 50th percentile) and 3rd, 10th, 90th, and 
97th curves were reported from the analysis of weight-for-length/height.  
4.1.3 Height distance from target height 
In all 26,636 healthy subjects (12,895 girls, 13,741 boys) that were collected for height-for-
age reference database comprised the TH reference population data. The subjects of the 
study group older than 15 years and with less than 1.0 cm height gain during the last 
follow-up year were considered as having reached their adult height (AH) (n = 3,481 girls 
and 886 boys). Mid-parental height (MPH) was the mean of parental heights, corrected for 
sex (-6.8 cm for girls and +6.8 cm for boys) and converted to SDS by using the former 
Finnish growth reference (from subjects born 1954-1972) (2), which was considered to better 
reflect the growth in the parents than the new reference (data from subjects born 1983 – 
2009).  
Firstly, the two commonly used TH formulas were compared to determine which 
achieved the most precise estimate of the AH in the reference population. The formula 
developed by Wright et al. is based on the regression line between MPH SDS and AH SDS 
(132). The formula developed by Hermanussen & Cole (133),TH SDS = 0.72 * (paternal 
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height SDS + maternal height SDS) / 2, has been recommended by the international 
consensus statement for the diagnosis and treatment of children with idiopathic short 
stature(153). It is based on correlation coefficients between parental and offspring height 
SDSs and parental height SDSs. Secondly, the differences between height SDS and TH SDS 
were calculated in the reference population in order to define age-specific reference values 
for height SDS distance from TH SDS using both TH formulas.  
Paired samples t-test was used to test the difference between the two TH formulas. 
4.1.4 Growth rate by age 
Calculation of the reference values for normal growth velocity was based on longitudinal 
growth data of the height reference population (height rate by age) and weight reference 
population (BMI rate by age). Variation in the growth rate over time was based on the fact 
that the distribution of the change in height SDS and BMI SDS at a fixed age interval is 
normally distributed with zero mean and SD of ǆ(2*(1-r)), in which r is the correlation 
coefficient between the height SDS and BMI SDS measurements at the ends of the interval 
(103). As the data were not measured at fixed ages, age groups were formed in order to 
obtain approximations for the correlations for fixed age intervals. Two different age 
classifications were used according to the routine measuring schedule adopted in primary 
care in order to utilize the data as exactly as possible: monthly until one year and yearly for 
whole age period rounding the age to the nearest integer (month or year). Then the 
correlations were calculated for all the possible pairs of age groups, and modeled by 
regression analysis in which the dependent variable was their Fisher’s transformation z = 
0.5*log((1+r)/(1-r)). The explanatory variables were the group averages of the difference and 
average of the pair of ages and/or some transformations of these values, if needed, to better 
capture the dependence structure between the correlation and age (154). In addition, 
separate models for two different age classifications were created. These four reported 
regression models can be used to predict the value of a correlation for any pair of 
observations using the back transformation formula r = (exp(2*z)-1)/(exp(2*z)+1) for the 
predicted value of z. With the known predicted value of correlation, the predicted value of 
SD for change can also be calculated by using the above SD formula. The standardized 
value of the change in height SDS and BMI SDS is then the actual change divided by its 
predicted value of SD. In the normal population, it is normally distributed with a mean of 
0.0 and SD of 1.0. In order to depict the normal variation of the growth rate over time, 
estimates of SD curves for different time intervals were plotted from each model. The 
goodness-of-fit for the regression model was assessed by creating different residual plots 
and plotting fitted curves for SDs together with corresponding data points. Parameter 
estimates were used to define formulas for growth rate reference values that are presented 
in Table 5A (height SDS aged 0 – 1 years), Table 5B (height SDS aged 1 – 12 years) and Table 
5C (BMI SDS aged 2 – 12 years) for girls and boys. These population-based cut-off values 
for growth rate are scalable for age without any limitation of fixed time intervals. 
4.2 GROWTH DISORDER COHORTS 
4.2.1 Turner syndrome cohort 
Longitudinal height data including 2,184 measurements for 136 girls with TS (born between 
1978 and 2009) were collected from three Finnish University Hospitals (Helsinki, Kuopio 
and Tampere). TS girls were identified from the hospitals’ patient registry according to the 
ICD-10 code (Q96). Clinical data including gestational age at birth, birth size, longitudinal 
growth data, parental heights, karyotype, the date of TS diagnosis, associated disorders, 
treatments, and medications were recorded. Twelve TS girls were excluded from the study 
population: three girls with type I diabetes, one with a malignant tumor, one with  
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Table 5. Regression formula with Fisher backtransformation and standard deviation formula for 
height SDS change at different ages, on functions of the mean age (mage) and age distance 
(dage) for girls and boys.  Formula (Coefficient * Estimate) gives the reference for height SDS 
changes aged 0 – 1 year (A) and 0 – 12 years (B), and BMI SDS changes aged 2 – 12 years 
(C).   
GIRLS  BOYS    
A Coefficient Estimate Coefficient Estimate 
 Intercept 2.1193 Intercept 2.0848    
 ¥GDJH -0.6335 sqrt(dage)          -1.1072    
 »¥PDJH -0.0439 log(mage)           0.0601    
 dage2 1.1981 (dage)2           0.3001    
 ¥GDJH»¥PDJH -0.5424 1/(mage)2          0.0016    
 »¥PDJHGDJH2 -0.9754 sqrt(dage)*log(mage)    0.3938    
     
B     
 Intercept 2.4330 Intercept 1.9251   
 ¥GDJH -0.0636 sqrt(dage)        -1.5671   
 »¥PDJH -0.1268 1/mage         -0.1977   
 mage3 0.0072 mage3         -0.0001   
 ¥GDJH»¥PDJH -1.223 sqrt(mage)       0.4186   
 ¥GDJHPDJH3 -0.0003 sqrt(dage)*mage3  -0.0007   
 mage3*ln(mage) -0.0028 sqrt(dage)*sqrt(mage)  0.4304   
     
C     
 Intercept 1.3835 Intercept 1.3901 
 ¥GDJH -0.7729 ¥GDJH -0.5144 
 ln(mage) 0.3614 mage 0.0870 
 ¥GDJHOQPDJH 0.1248   
 
 
hyperinsulinism and seven because of missing parental heights. The remaining TS cohort 
comprised of 124 (91.2 % of the original cohort) girls and their 2,020 height measurements 
(Table 6). All the TS girls were measured in the standard way with calibrated equipment by 
specially trained nurses during scheduled, routine visits at well-baby clinics, school health 
care or control visits at the hospital outpatient clinics. Potentially false measurements, 
typing errors, missing values, or duplicate recordings were detected in the longitudinal 
height data using scatter plots and then either corrected or excluded. Height data were 
used only until the start of any growth promoting therapy. Height was converted to z-
scores in the new Finnish growth reference (I). 
4.2.1 Celiac disease cohort 
Children aged 0-16 years with CD were identified in patient registries of three University 
Hospitals in Finland (Helsinki, Kuopio and Tampere) according to International 
Classification for Diseases version 10 code for CD (K90.0) and clinical and auxological data 
were collected retrospectively from the patient files. In all cases, the diagnosis of CD was 
based on the histological evaluation of duodenal biopsies conducted by a pathologist. The 
biopsy specimens were classified as having either moderate, subtotal or total villous 
atrophy. In five cases, the degree of villous atrophy was unavailable. Age at diagnosis, 
preceding symptoms, laboratory results [hemoglobin, total immunoglobulin A (IgA), and 
IgA transglutaminase (tTG) and endomysium (EMA) antibodies], and histological data 
were registered. Growth data were collected until the time of diagnosis.  Height and weight 
measurements were transformed into z-scores according to the new Finnish growth 
reference (I). Potentially false measurements, typing errors, missing values, or duplicated 
recordings were evaluated by scatter plots, and then either corrected or excluded.  
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Chi2 -test was used to test the differences between girls and boys for symptoms and 
histopathological findings, and independent samples t-test for growth and laboratory 
findings. The general linear model for repeated measurements was used for testing the 
difference of HSDS against the reference population mean height. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Flow chart for celiac disease cohort. 
The initial study cohort consisted of 268 children (59% girls) (Figure 9). The following 
exclusion criteria were applied: another disease or medication possibly affecting growth (n 
= 30), unavailable growth data (n = 33), and the absence of the date of CD diagnosis (n = 28). 
After excluding these cases, the final study cohort consisted of 177 children (106 girls and 
71 boys with 1051 and 601 height and weight measurements prior to diagnosis, 
respectively).  
The characteristics of the CD patients are presented in Table 7. Altogether 60 % of the 
patients were girls (P < 0.01). The median age at diagnosis was 6.2 years (range 0.9 – 15.9) in 
girls and 7.1 years (0.8 – 16.1) in boys (P=n.s.). At the time of diagnosis 33% of the CD 
children were asymptomatic and the most common symptom preceding the CD diagnosis 
was recurrent abdominal pain in 27% of children. Diarrhea or loose stools was found in 12 
% and constipation in 4% of the patients. Diarrhea with abdominal pain was more 
prevalent in boys (P < 0.05). Histopathological findings showed a more severe grade of 
238 subjects 
Exclusion 1: Another disease or medication potentially 
affecting growth (30 subjects) 
 congenital syndrome (12) 
 diabetes mellitus type I (10) 
 asthma (3) 
 inflammatory bowel disease (3) 
 juvenile idiopathic arthritis (1) 
 hypothyroidism (1) 
 precocious puberty (1) 
Exclusion 2: Unavailable growth data (33 subjects) 
FINAL DATABASE 
 177 subjects 
 106 girls (60%) with 1,051 measurements 
 71 boys (40%) with 601 measurements 
INITIAL DATABASE 
Children aged 0 – 16 years with celiac disease (ICD-10 code K90.0) 
 268 subjects 
 157 girls (59%) and 111 boys (41%) 
205 subjects 
Exclusion 3: Unavailable date of diagnosis (28 subjects) 
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atrophy in boys with a total villous atrophy in 23 (32%), in comparison to 15 (14%) girls (P < 
0.01). The majority of CD children had an increased level of IgA antibodies to tTG (mean 
103 U/mL in girls and 133 U/mL in boys, P = n.s.) and EMA (titers 767 and 992, P = n.s.). 
IgA-tTG and EMA antibodies were in the normal range in nine patients and two of these 
children had also total IgA deficiency. At the time of diagnosis, hemoglobin was below the 
age-specific reference range in 31% of CD children (Table 7). 
In the CD cohort at the time of diagnosis, the mean values  of HSDS and BMI SDS were -
0.45 (SD 1.08) and -0.25 (1.23) in girls and -0.58 (1.17) and -0.44 (1.08) in boys, respectively 
(Table 5). Overall, girls with CD were shorter than healthy children at 2 years and in boys at 
1 year before diagnosis of CD was made (P < 0.05) (Figure 10). Differences in BMI-for-age 
between the CD patients and healthy children were not statistically significant for either 
girls or boys (data not shown).  
4.2.3 Statistical analyses 
The evaluation between multi-ethnic and population specific growth references was 
performed with longitudinal height data of 124 Finnish TS girls (60 with karyotype 45,XO) 
containing 2,020 measurements that were assessed either by using the WHO charts (20) or 
new Finnish growth reference (I). The accuracy of both growth references for detecting 
growth patterns associated with TS was studied by calculating the cumulative percentage 
of TS girls with at least one measurement either below the 3rd (screening specificity 97%) or 
the 1st (specificity 99%) height-for age percentile.  
Analyses for diagnostic accuracy of new Finnish growth references for target conditions 
(TS and CD) were performed with six growth screening parameters: 
1. Height-for-age in comparison to the population mean (HSDS rule) 
2. TH, i.e. the maximum HSDS distance from TH SDS (TH SDS rule)  
3. Change in height rate, i.e. the maximum change in height SDS over time ('HSDS 
rule 
4. BMI-for-age in comparison to the population mean (BMI SDS rule) 
5. ȱ ȱ ȱǰȱ ǯǯȱ ȱ¡ȱȱ ȱȱȱȱ ȱ ǻ̇ȱ
rule), 
that were evaluated one by one and in combination (6. Combination rule). The first three 
were combined for TS cohort, and all five for CD cohort, respectively. 
First, the individual probability for abnormal growth screening (using HSDS, TH SDS, 
'HSDS or the combination rule for TS cohort, and HSDS, TH SDS, 'HSDSǰȱǰȱ̇ȱ
and combination rule for CD cohort) were calculated for each girl in the TS cohort and in 
each child in the CD cohort, and for the reference population using logistic regression. 
Secondly, these probabilities were used to assess the diagnostic accuracy of growth 
screening. The diagnostic accuracy was depicted by area under the curve (AUC) –values 
from Receiver Operating Characteristic (ROC) curves against the reference population. 
Thirdly, the optimal cut-off points (OCP) for each screening rule were defined so that 
sensitivity and specificity of the rule obtained the maximal values (OCP was chosen at the 
point of maximum of sensitivity2 + specificity2). The cumulative diagnostic performance of 
each screening rule was also evaluated by age.  
 
 
 
 
30
31
 
 
T
ab
le
 6
. 
C
h
ar
a
ct
er
is
ti
cs
 o
f 
th
e 
1
2
4
 g
ir
ls
 w
it
h
 T
u
rn
er
 s
yn
d
ro
m
e.
 
  
T
u
rn
e
r 
T
u
rn
e
r 
T
u
rn
e
r 
 
4
5
,X
O
 k
a
r y
o
ty
p
e
 
O
th
e
r 
k
a
ry
o
ty
p
e
s 
A
ll
 
S
a
m
p
le
 s
iz
e
, 
n
 
6
0
 
 
6
4
 
 
1
2
4
 
 
N
u
m
b
e
r 
o
f 
m
e
a
su
re
m
e
n
ts
, 
co
u
n
t 
9
8
0
 
 
1
0
4
0
 
 
2
0
2
0
 
 
N
u
m
b
e
r 
o
f 
m
e
a
su
re
m
e
n
ts
 p
e
r 
g
ir
l,
 m
e
a
n
 (
S
D
) 
1
6
.3
 
(7
.1
4
) 
1
6
.3
 
(6
.9
5
) 
1
6
.3
 
(7
.0
1
) 
 
 
 
 
 
 
 
H
e
ig
h
t 
S
D
S
a
, 
m
e
a
n
 (
S
D
),
 a
ll
 m
e
a
su
re
m
e
n
ts
 
-2
.2
4
 
(0
.8
0
) 
-2
.0
7
 
(1
.0
8
) 
-2
.1
5
 
(0
.9
6
) 
W
e
ig
h
t 
fo
r 
h
e
ig
h
t 
S
D
S
a
, 
m
e
a
n
 (
S
D
),
 a
ll
 m
e
a
su
re
m
e
n
ts
 
-0
.0
2
 
(1
.0
5
) 
0
.0
1
 
(1
.4
0
) 
-0
.0
1
 
(1
.2
5
) 
B
M
I 
fo
r 
a
g
e
 S
D
S
a
, 
m
e
a
n
 (
S
D
),
 a
ll
 m
e
a
su
re
m
e
n
ts
 a
ft
e
r 
2
 y
 
0
.0
2
 
(0
.8
8
) 
0
.0
5
 
(1
.3
2
) 
0
.0
3
 
(1
.1
4
) 
 
 
 
 
 
 
 
G
e
st
a
ti
o
n
a
l 
a
g
e
 (
w
e
e
k
s)
 (
n
=
9
1
)d
, 
m
e
a
n
 (
S
D
) 
3
8
.9
 
(1
.7
1
) 
3
8
.9
 
(2
.3
4
) 
3
8
.9
 
(2
.0
4
) 
B
ir
th
 l
e
n
g
th
 (
cm
) 
(n
=
9
1
),
 m
e
a
n
 (
S
D
) 
4
7
.3
 
(1
.9
4
) 
4
7
.6
 
(2
.9
9
) 
4
7
.5
 
(2
.5
3
) 
B
ir
th
 w
e
ig
h
t 
(k
g
) 
(n
=
9
1
),
 m
e
a
n
 (
S
D
) 
2
.9
9
 
(0
.4
9
) 
3
.0
3
 
(0
.6
5
) 
3
.0
1
 
(0
.5
7
) 
B
ir
th
 l
e
n
g
th
 S
D
S
b
 (
n
=
9
1
),
 m
e
a
n
 (
S
D
) 
-1
.2
3
 
(0
.9
8
) 
-0
.9
0
 
(1
.3
2
) 
-1
.0
7
 
(1
.1
7
) 
B
ir
th
 w
e
i g
h
t 
S
D
S
b
 (
n
=
9
1
),
 m
e
a
n
 (
S
D
) 
-1
.0
4
 
(1
.1
7
) 
-0
.9
6
 
(1
.2
5
) 
-1
.0
0
 
(1
.2
0
) 
 
 
 
 
 
 
 
P
a
te
rn
a
l 
h
e
ig
h
t 
S
D
S
d
, 
m
e
a
n
 (
S
D
) 
0
.1
7
 
(0
.9
5
) 
-0
.1
7
 
(1
.0
8
) 
-0
.0
1
 
(1
.0
3
) 
M
a
te
rn
a
l 
h
e
ig
h
t 
S
D
S
d
, 
m
e
a
n
 (
S
D
) 
0
.0
7
 
(0
.9
2
) 
0
.0
2
 
(1
.0
4
) 
0
.0
5
 
(0
.9
8
) 
M
id
 -
p
a
re
n
ta
l 
h
e
ig
h
t 
S
D
S
c ,
 m
e
a
n
 (
S
D
) 
0
.1
2
 
(0
.7
1
) 
-0
.0
8
 
(0
.7
6
) 
0
.0
2
 
(0
.7
4
) 
 
 
 
 
 
 
 
A
g
e
 a
t 
d
ia
g
n
o
si
s 
(y
e
a
rs
) 
(n
=
1
1
8
)e
, 
m
e
d
ia
n
 (
ra
n
g
e
) 
0
.0
 
(0
-1
7
.0
) 
5
.3
 
(0
-1
5
.9
) 
3
.6
 
(0
-1
7
.0
) 
P
e
ri
n
a
ta
l 
d
ia
g
n
o
se
s,
 c
o
u
n
t 
 
3
1
 
 
1
2
 
 
4
3
 
 
 
 
 
 
 
 
 
K
a
r y
o
ty
p
e
, 
n
 (
%
) 
 
 
 
 
 
 
4
5
,X
O
  
6
0
 
(1
0
0
) 
 
 
6
0
 
(4
8
) 
4
5
,X
O
 a
n
d
 4
6
, 
X
X
 
 
 
1
3
 
(2
0
) 
1
3
 
(1
1
) 
4
5
,X
O
 a
n
d
 (
4
6
,X
,i
X
 o
r 
4
6
,X
,i
d
ic
(X
))
 
 
 
1
0
 
(1
6
) 
1
0
 
(8
) 
4
6
,X
, 
iX
 o
r 
4
6
, 
X
, 
id
ic
(X
) 
 
 
5
 
(8
) 
5
 
(4
) 
4
5
,X
O
/
4
7
,X
X
X
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
4
 
(6
) 
4
 
(3
) 
O
th
e
r 
 
 
3
2
 
(5
0
) 
3
2
 
(2
6
) 
a F
in
n
is
h
 g
ro
w
th
 r
ef
er
en
ce
 1
9
8
3
-2
0
0
8
 (
I)
, 
a
ll 
m
ea
su
re
m
en
ts
 
b
N
ew
 F
in
n
is
h
 g
ro
w
th
 r
ef
er
en
ce
s 
fo
r 
b
ir
th
 s
iz
e 
(1
5
5
) 
c F
in
n
is
h
 g
ro
w
th
 r
ef
er
en
ce
 1
9
5
9
-7
1
 (
2
) 
d
N
o
t 
fo
u
n
d
 f
o
r 
3
3
 T
S
 g
ir
ls
 
e N
o
t 
fo
u
n
d
 f
o
r 
6
 T
S
 g
ir
ls
 
 
31
32 
 
 
Table 7. Clinical characteristics at diagnosis in 177 children with celiac disease. 
  Girls Boys 
Total, count (%)  106 (60) 71 (40) 
Age at diagnosis (years),  
median (min-max) 
 6.2 (0.9–15.9) 7.1 (0.8–16.1) 
Height and weight measurements,  
count  
 
1051 601 
Height and weight measurements per child,  
mean (SD) 
 
9.9 (6.0) 8.5 (4.8) 
    
Presenting symptoms, count (%)    
Diarrhea and abdominal pain  20 (19) 25 (35) 
Constipation and abdominal pain  10 (9) 2 (3) 
Only abdominal pain  28 (26) 11 (16) 
Asymptomatic  30 (28) 18 (25) 
Not known  18 (17) 15 (21) 
    
Histological findings in duodenal biopsy,  
count (%) 
   
Moderate villous atrophy  39 (37) 22 (31) 
Subtotal villous atrophy  47 (44) 26 (37) 
Total villous atrophy  15 (14) 23 (32) 
Not known  5 (5) 0 (0) 
    
Laboratory findings, median (min-max)    
IgA-tTG (U/mL)  100 (10–300) 100 (9–1,110) 
IgA-EMA (titer)  250 (5–5,000 ) 250 (10–10,240) 
Blood Hb (g/L)  122 (87–139) 122 (80–161) 
    
Height-for-age SDSa, mean (SD)  -0.45 (1.1) -0.58 (1.2) 
BMI-for-age SDSa, mean (SD)  -0.25 (1.2) -0.44 (1.1) 
    
Height distance from TH SDS, mean (SD)  -0.57 (1.2) -0.67 (1.1) 
Target height (TH)  SDSb, mean (SD)  -0.05 (0.6) -0.06 (0.8) 
aIn comparison to the new Finnish growth reference (I) 
bTH formula 0.791 x mean parental height  (MPH) SDS – 0.147 for girls and 0.886 x MPH SDS – 
0.071 for boys (III) 
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Figure 10. Mean height SDS (95% CI) in girls (solid line and circles) and boys (dashed line and  
squares) with celiac disease 0 – 5 years prior to the diagnosis in comparison to population 
based reference (I). The asterisks indicate statistically significant difference (P < 0.05) 
4.3 AUTOMATED GROWTH MONITORING PROGRAM 
The prospective one-year AM intervention was performed in the primary care between 
March 2008 and February 2009. Data collection for AM intervention year was performed as 
a part of the growth reference study for height reference (Figure 8). The whole child 
population between 0.01 and 12 years was included in the study and covered by the free-of-
charge national health monitoring program (150). One year before the AM intervention 
year (between March 2007 and February 2008) was used as the control year with SM 
strategy, to obtain a comparator for the evaluation of the change in effectiveness.  
The Finnish child population had been screened from infancy to early adolescence for 
abnormal linear growth according to the nationwide SM strategy (Table 2) (2-4). In this 
programme, if the primary care nurse considers the growth to be abnormal, then she/he 
consults the primary care physician who performs an assessment or baseline investigations 
and may refer the child to secondary care.  
During the control year an average of 32,718 children were measured 76,926 times, and 
during AM intervention year 32,404 children were measured 77,409 times (see Figure 26). 
The growth of 22,135 (68.3%) children measured during the AM intervention year had been 
assessed in the control year.  
4.3.1Automated growth monitoring intervention 
The one-year AM intervention was run concurrently with the ongoing SM strategy, and is 
presented in Figure 11. The AM included two additional automated steps: firstly, the 
longitudinal growth data of each measured child were automatically analysed by the 
computerised screening algorithms integrated into the EHR system. Secondly, if the  
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Figure 11. The one-year automated growth monitoring intervention process: 1. Measuring 
children and imputing growth data to electronic health records, 2. Automated growth 
monitoring, 3. Consultation of pediatric endocrinologist, 4. Consultant’s advice to the primary 
care. 
automated screening result was abnormal, the individual’s growth and clinical data were 
automatically transferred as an online growth consultation to a paediatric endocrinologist 
in secondary care. An e-mail was then sent to the primary care nurse which included an 
analysis of the growth pattern and advice for further management. During the AM 
intervention, a referral to secondary care may have originated from the nurse and primary 
care physicians’ own interpretation of the child’s growth pattern or after the consultation 
response. 
4.3.2 Analyses for effectiveness of automated growth monitoring   
The primary effectiveness outcomes were the referral rates for suspected abnormal growth,  
the diagnostic yield of growth disorders, and the delay in their diagnosis during the AM 
intervention year versus the control year (detailed in Figure 12). Children with previously 
diagnosed growth disorders were filtered out from the study population before the study, 
and only previously undiagnosed growth disorders were registered by using the European 
Society for Paediatric Endocrinology classification of primary and secondary growth 
disorders and idiopathic short stature (ISS) (82). 
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Figure 12. Automated growth monitoring (AM) intervention that was integrated into an 
electronic health record during the AM. Screening algorithms are presented in Table 4 on page 
19. 
The absolute risks (risk ratios; RRs) for referral for abnormal growth and the RRs for rate 
of new growth disorder diagnoses were calculated.  The diagnostic yield was defined as the 
number of measured children per single newly diagnosed growth disorder.  Poisson 
regression was used to assess if the number of referrals or new cases of growth disorders 
differed between the AM and control years. RRs in the two years were compared by the 
confidence interval (CI) analyses using 95% CI. The Fisher’s exact test was used in the 
comparison between the proportions of children in the SM and AM intervention years.  
Excel 2007 (Microsoft Corporation, Burbank, WA, United States), SPSS version 19 (IBM 
Corporation, Armonk, NY) and R statistical software were used in the analyses conducted 
in this study. P values less than 0.05 were considered statistically significant. 
SETTING: Primary and secondary care in one municipality in Finland  
POPULATION: The whole child population between 0.01 and 12 years covered by the free-of-charge national health 
monitoring program (2-4). 
REFERENCE YEAR March 2007-February 2008  
 
STANDARD GROWTH MONITORING (SM) STRATEGY (the same strategy used in the population since 1989):  
Ȋȱurses trained in auxology measure the children and enter the data in the electronic health record (EHR) system 
Ȋȱȱ ȱȱȱȱȱ¢ȱȱȱ-based growth charts    
ȊȱȱȱǻȱŚ) are interpreted manually by the primary care nurses  
Ȋȱȱȱ¢ȱȱȱ ȱȱȱȱȱȱ¢ȱ 
INTERVENTION YEAR March 2008-February 2009 
 
AUTOMATED GROWTH MONITORING (AM) STRATEGY:  
Ȋȱ ȱ	ȱȱ ȱȱȱrimary care EHR to complement the SM strategy:    
1. Computerized screening algorithms (Figure 8)   
2. Automated online consultation of a pediatric endocrinologist if the automated screening result was abnormal  
Ȋȱȱȱȱȱȱȱȱȱ ȱȱȱȱȱ¢ȱ 
COMPARISON OF AM AND SM 
 
EFFECTIVENESS OUTCOMES (AM intervention versus SM reference year):   
Ȋȱl for suspected abnormal growth 
Ȋȱȱ¢ȱȱ ȱȱ 
Ȋȱȱ¢ȱȱ ȱȱǻ from the first abnormal screening result to the actual referral to secondary care)   
 
METHODS:   
1. A retrospective application of the computerized screening algorithms in the lifelong growth database of all children ĺ 
the true number and timing of abnormal growth screening results in SM and AM years  
2. Review of primary care medical records of all children referred from primary care to secondary care either in the SM or 
AM years ĺ those referred for suspected abnormal growth included in the further analyses  
3. Review of secondary care medical records of children referred for suspected abnormal growth until termination of the 
diagnostic work-up (follow up until 30th August 2011)   
4. Registration of the previously undiagnosed growth disorders according to ESPE classification (83) 
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4.4 APPROVAL OF ETHICS COMMITTEE 
Permission for the study was obtained from Espoo Municipality Institutional Review Board 
(I & V) and the ethics committee of the Kuopio University Hospital (II, III & IV), and 
Hospital for Children and Adolescents, Helsinki University Hospital (V). No contact with 
the study subjects was considered necessary since the data were analysed anonymously. 
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5 Results 
5.1 GROWTH REFERENCES 
Figure 13 shows the new Finnish growth reference 1983–2008 for length/height-for-age in 
comparison with the old growth reference 1956–1973. The mean birth lengths in the 
reference 1983–2008 population were 50.3 cm in girls and 51.1 cm in boys compared to 50.2 
cm and 50.7 cm in the old reference, respectively. The mean birth lengths of full-term babies 
in the  new Finnish growth references for birth size from the year 2013 is 50.1 cm in girls 
and 51.0 cm in boys (149) suggesting that the population selected for the new length/height 
reference is a fair representation of the contemporary Finnish population. The mean adult 
height of girls increased by 1.9 cm (from 165.3 cm in the reference 1956–73 to 167.2 cm in 
the reference 1983–2008 population); the mean adult height between the cohorts for boys 
increased by 1.8 cm from 178.9 cm to 180.7 cm, respectively. 
In the growth reference 1983-2008, girls and boys at the age of 18 were 1.4 and 1.1 cm 
taller, respectively than girls and boys in the reference 1956-73 at the age of 20 years. This 
indicates that there still is a positive secular change occurring in adult heights in Finland 
5.1.1 Secular trends in height  
The growth pattern resulting in the increased adult height had distinct age- and sex-specific 
features (Figure 14). Between the ages of 0 to 20 years, subjects in the growth reference 
1983–2008 were generally taller than subjects in the reference 1956–73; however, the 
difference was almost nonexistent in boys and negative in girls during infancy 
(approximately 5 to 11 months of age). In that age range, girls from the 1983–2008 
population were, on average, 0.2 cm/0.07 SDS shorter than girls from the growth reference 
1956–73. The positive secular change was more substantial in boys at all ages even though 
the adult height increase was similar in boys and girls (1.8 cm/0.27 SDS and 1.9 cm/0.32 
SDS, respectively). The maximum difference in height in boys was seen around the age of 
13 years (a 5.6 cm/0.70 SDS increase when compared to the reference 1956–73 population). 
In girls, the maximum difference between the two reference periods seemed to occur 
earlier, around at the age of 11.5 years, and was less than that observed in boys (2.8 cm/0.40 
SDS). 
The total number of length/height measurements from different age groups of the height 
reference 1983–2008 population and the percentage of measurements outside the mean 
±2SD of the existing height reference 1956–73 are shown in Table 8. On average, 
measurements in girls (3.4%, range 1.2–5.6%) and boys (4.3%, range 1.9%–8.9%) were above 
+2SD which was clearly different from the expected 2.3% of normally distributed height).  
The proportion of measurements above +2SD was less than 2.3% in girls aged 4 to 18 
months and in boys aged 5 to 10 months. The highest proportions of measurements above 
+2SD were seen in girls aged 11 to 12 years and in boys aged 12 to 13 years. Only 0.9% of 
measurements in girls (range 0.4–1.8%) and 0.5% (range 0.1–1.0%) of measurements in boys 
were below –2SD of the reference 1956–73. 
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Figure 13. The new Finnish length/height-for-age reference (mean ±2 SD, solid lines). Curves 
based on 181,785 measurements from 26,636 full-term healthy subjects born between 1983 
and 2008 compared to the current Finnish growth reference based on subjects born between 
1956 and 1973 (mean ±2 SD, dashed lines). A: boys aged 0–2 years; B: girls aged 0–2 years; 
C: boys aged 2–20 years; and D: girls aged 2–19 years. 
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Figure 14. Age- and sex-specific features of the secular change in mean length/height in 
Finland. Comparison between growth reference 1956–1973 population subjects (those born 
between 1956 and 1973) and reference 1983–2008 population subjects (those born between 
1983 and 2008). Curves indicate differences from the reference 1956–1973 population in: A: 
mean height in cm from birth to age 2 years; B: mean height in cm from age 2 to 20 years; C: 
mean height in SD units from birth to age 2 years; and D: mean height in SD units from age 2 
to 20 years. Dashed line = girls; solid line = boys. 
 
5.1.2 Multi-ethnic versus population-based growth references 
The cumulative percentage (i.e sensitivity) for detecting TS was significantly higher when 
the population specific growth reference was used (Figure 15). By the age of 2 years, 72% 
and 55% of all TS girls (81% and 67% of 45,XO girls) had at least one height measurement 
below the 3rd and 1st percentiles, respectively, in population specific growth reference. In 
contrast, only 36% and 20% of all TS girls (41% and 23% of 45,XO girls) had a height 
ȱ  ȱ ȱ ȱ  ȱ ȱ 
ȱ ȱ  ȱ ȱ ǻǂŖǯŖŖŗǰȱ
McNemar’s test). From 2 to 5 years, the gap in the cumulative sensitivity between the two 
growth references grew even wider, especially if the 1st percentile was used as the cutoff 
(Figure 15). 
 
39
40 
 
 
Figure 15. Percentage of girls with Turner syndrome (TS) with height for age less than the third 
(A) or the first (B) percentile of either the Finnish (upper solid lines) or the World Health 
Organization (WHO) (lower dashed lines) growth reference for all girls with TS (All, n=124) and 
those with an XO karyotype (45,XO, n=60). 
5.1.3 Weight-for-length/height reference 
New median weight-for-length/height percentile (3rd, 10th, 50th, 90th, 97th) curves for girls and 
boys in the weight reference 1983–2008 population are compared to median curve of the 
reference 1959–71 population (Figure 16). The median weight-for-length/height curves for 
both populations were nearly superimposable up to a height of 140 cm (corresponding to a 
height age of 10 years) in boys and 155 cm (a height age of 12 years) in girls. Subsequently, 
a slight increase in median weight-for-length/height was observed in reference 1983–2008 
population subjects. 
5.1.4 BMI-for-age reference 
BMI percentile curves (3rd, 10th, 50th, 90th, and 97th) for Finnish children and adolescents aged 
2 to 18 years are shown in Figure 17. BMI percentile curves for Finnish children have not 
been previously published. The median (50th percentile curve) BMI-for-age declined slightly 
from the age of 2 years until approximately 6 years in both girls and boys and then started 
to increase. The point at which the BMI values increase is called the ‘adiposity rebound’ 
(35). This took place later in the lower percentiles in comparison to the higher values 
(Figure 17). Median BMI-for-age was slightly higher in boys than in girls between the ages 
of 2 to 5 years and 8 to 13 years (up to 0.3 kg/m2). After the age of 15 years, the difference 
between boys and girls increased rapidly with boys having up to a 1.1 kg/m2 higher median 
BMI than girls by the age of 18 years. 
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Table 8. Number of height measurements in the present population and percentage of 
measurements < -2SD and > +2SD when compared to the reference population. 
 Boys 
Boys outside the ±2SD 
range of  
the old growth reference 
 
Girls 
Girls outside the ±2SD 
range of  
the old growth reference 
Age 
group Count 
%  
<-2SDS 
% 
>+2SDS 
 
Count 
% 
 <-2SDS 
% 
>+2SDS 
<1mo 4178 0.3 6.5  3969 0.7 5.3 
1-2mo 4943 0.3 6.0  4596 0.4 5.4 
2-3mo 3285 0.1 4.5  3161 0.8 3.6 
3-4mo 5658 0.3 3.7  5262 0.8 3.1 
4-5mo 4230 0.5 3.0  4016 1.1 2.2 
5-6mo 4526 0.8 2.1  4310 1.4 1.2 
6-8mo 5105 0.7 1.9  4805 1.7 1.3 
8-10mo 4500 0.8 1.9  4236 1.7 1.4 
10-12mo 3268 0.9 2.4  3233 1.2 1.5 
12-18mo 4764 0.6 3.0  4491 1.0 2.0 
18-24mo 4010 0.5 4.2  3794 0.5 3.6 
2-3y 4195 0.4 4.4  3872 0.4 3.4 
3-4y 4004 0.3 4.5  3757 0.5 3.9 
4-5y 1473 0.4 4.5  1339 0.8 4.3 
5-6y 3609 0.3 5.2  3369 0.5 3.9 
6-7y 3386 0.2 4.8  3290 0.6 4.3 
7-8y 2405 0.3 5.5  2141 0.7 4.4 
8-9y 2689 0.2 6.0  2608 0.6 4.4 
9-10y 2648 0.3 5.8  2459 0.5 4.5 
10-11y 1504 0.4 4.8  1444 1.2 4.8 
11-12y 2621 0.4 5.4  2646 0.8 5.6 
12-13y 1993 0.4 8.9  2010 1.4 4.2 
13-14y 2443 0.3 8.1  2503 1.8 4.3 
14-15y 2071 0.8 4.0  1999 1.3 4.3 
15-16y 1566 1.0 3.2  1551 1.2 3.6 
16-17y 1824 0.8 2.7  1816 1.4 3.9 
>17y  735 1.0 3.0  661 1.2 4.4 
Total 87633 0.5 4.3  83338 0.9 3.4 
Total number of girls = 12,895 girls; boys = 13,741 boys.  
Population includes subjects born between 1983 and 2008; old growth reference includes subjects born 
between 1956 and 1973 (2-4). Birth measurements are not shown. 
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Figure 16. The new Finnish weight-for-length/height percentile (3rd, 10th, 50th, 90th, 97th) 
curves. Curves based on 428,526 length/height and weight measurements taken from 73,659 
healthy subjects in the weight reference 1983–2008 population (those born between 1983 and 
2008; solid lines) compared to the median weight-for-length/height curve of the reference 
1956–73 population (those born between 1956–1973; dashed line). A: boys 45–90 cm; B: boys 
90–180 cm; C: girls 45–90 cm; D: girls 90–190 cm. 
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Figure 17. The new Finnish BMI-for-age reference percentile curves. The 3rd, 10th, 50th, 90th, 
and 97th curves are shown for children and adolescents aged 2–18 years. A: boys; B: girls. 
 
5.2 SCREENING CUT-OFF VALUES FOR ABNORMAL GROWTH 
5.2.1 Height-for-age distance from TH and growth rate.  
The modified Wright (132) formula in the reference subpopulation with known AHs 
(n=3,481) resulted in the following TH formulas for boys and girls (Figure 18):  
 
Boys’ THSDS = 0.89 * MPH SDS – 0.07  
Girls’ TH SDS = 0.79 * MPH SDS – 0.15 
 
These were compared to the Hermanussen and Cole formula (133) with respect to the 
AH SDS and height SDS at ages 15-18 years (Figure 19). The mean (SD) difference between 
height SDS and TH SDS was 0.00 (0.80) for girls, and 0.00 (0.79) for boys when using the 
modified formula by Wright et al., and -0.14 (0.81) and -0.07 (0.79), respectively, when using 
the formula of Hermanussen and Cole (P = not significant for boys, ȱ ǂȱ ŖǯŖśȱ for girls) 
(Figure 18). In addition, the mean difference between AH SDS and TH SDS was 
significantly smaller when the modified Wright formula was used for girls, and this was 
true in virtually all age groups from 0 to 12 years (ȱǂȱŖǯŖś), and especially in short and tall 
children (data not shown). As the formula devised by Wright at al. appeared to be more 
concordant with the AH SDS and childhood height SDS than that of Hermanussen and 
Cole, it was selected for further use.  
Age-specific reference values for height SDS distance from TH SDS were calculated, and 
cut-offs in 95% and 98% specificity are shown in the Table 9. The cut-off values at a 
specificity of 95% ranged from 1.5 to 1.9, and the corresponding cut-offs for 98% specificity 
were 1.8 to 2.3 for both girls and boys in the age groups of 0 to 18 years. 
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Figure 18. Adult height SDSs of 886 healthy boys and 3,481 girls of the Finnish growth 
reference population (I) plotted against their mid-parental height (MPH) SDSs. The regression 
line was used for the modified formula of target height TH SDS = 0.89 * MPH SDS – 0.07 for 
boys, and TH SDS = 0.79 * MPH SDS – 0.15 for girls.  
 
 
Figure 19. Comparison of the modified target height formula devised by Wright and Cheetham 
(132) and the formula of Hermanussen and Cole (133) in the reference population. Observed 
mean HSDS difference from the target height SDS is shown for the boys (A) and girls (B) in the 
reference population that had reached their AH (B) subdivided into different age groups (years). 
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Table 9. Age-specific cut-off values (95% and 98% specificity) for height SDS distance from 
target height (TH) SDS according to the modified TH formula devised by Wright and Cheetham 
(132) calculated from the reference values shown in Figure 18. 
Boys Age         
Specificity 0-1 1-2 2-3 3-4 4-5 5-6 6-7 7-8 8-9 
95% 1.9 1.8 1.8 1.7 1.7 1.7 1.6 1.6 1.6 
98% 2.3 2.1 2.1 2.0 2.1 2.0 2.0 2.0 2.0 
 9-10 10-11 11-12 12-13 13-14 14-15 15-16 16-17 17-18 
95% 1.7 1.6 1.6 1.9 1.9 1.8 1.7 1.6 1.5 
98% 2.0 1.9 1.9 2.2 2.3 2.2 2.0 1.8 1.8 
          
 Age         
Girls 0-1 1-2 2-3 3-4 4-5 5-6 6-7 7-8 8-9 
95% 1.9 1.8 1.8 1.7 1.7 1.7 1.7 1.7 1.6 
98% 2.3 2.2 2.1 2.0 2.1 2.0 2.0 2.0 1.9 
 9-10 10-11 11-12 12-13 13-14 14-15 15-16 16-17 17-18 
95% 1.6 1.8 1.8 1.8 1.6 1.5 1.5 1.5 1.5 
98% 1.9 2.1 2.2 2.1 1.9 1.8 1.8 1.8 1.8 
 
Reference values for growth velocity (height SDS and BMI SDS) could be calculated 
between two measurements in free age intervals that are based on regression formula given 
in Table 5. As an example, cut-off values for height rate (decrease or increase) are shown 
with 99% specificity at fixed time intervals in the preceding 0.25, 0.5 and 0.75 years for 
children 0 to 1 years of age, and in the preceding 1, 3 and 5 years in children 1 to 12 years of 
age, respectively, in Figure 20. Understandably, cut-off values were showed greater 
tolerance over longer time range, and during infancy and puberty. 
Finnish and international (IOTF) percentile curves defining overweight were nearly 
superimposable in girls with the maximum difference of only 0.7 kg/m2. In boys, the largest 
difference (up to -1.2 kg/m2) between the two overweight curves was seen between the ages 
of 2 to 6 years with the Finnish overweight curve being lower than the IOTF curve. 
The cut-off curves for overweight and obesity (i.e., a BMI of 25 and 30 kg/m2 at the age of 
18 years) were the 87.8th percentile and 98.2nd percentile in girls and the 78.2nd percentile and 
95.6th percentile in boys, respectively.  
The cut-off curves for grade 1, 2, and 3 thinness (i.e., BMIs of 18.5, 17, and 16, 
respectively) were at the 17.9th, 5.0th, and 1.3rd percentiles in girls and the 12.1st, 3.3rd, and 
1.0st percentiles in boys, respectively 
5.2.2 BMI-for-age cut-offs for thinness, overweight, and obesity 
Finnish cut-off curves passing through BMIs of 30, 25, 18.5, 17, and 16 kg/m2 at the age of 18 
years (corresponding to obesity, overweight and grade 1, 2, and 3 thinness, respectively) 
were calculated for Finnish children (Figure 21). A comparison of the Finnish “normal area 
BMI” (i.e., between grade 2 thinness and overweight) with respect to international data is 
also provided (135,136). 
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Figure 20. Age-specific cut-off values (99% specificity) for height SDS rate for children aged 0 
to 1 year; boys = A, girls = B in the preceding 0.25, 0.5 and 0.75 years, and aged 1 to 12 
years; boys = C, girls = D in the preceding 1, 3 and 5 years. 
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Figure 21. Finnish BMI-for-age percentile curves for grade 3 and 2 thinness, overweight, and 
obesity. The percentiles passing through BMIs of 16, 17, 25, and 30 kg/m2 at the age of 18 
years and the ‘normal BMI area’ between percentiles of grade 2 thinness and overweight 
(shaded area) are shown. The corresponding BMI-for-age percentile curves from multi-ethnic 
data (dashed lines) indicate grade 2 thinness and overweight (International Obesity Task Force 
international reference) (135,136). A: boys; B: girls. 
 
 
5.3 GROWTH MONITORING ACCURACY FOR TARGET CONDITIONS 
5.3.1 Turner syndrome 
With either HSDS rule or TH SDS rules, the screening accuracy was slightly better for 
45,XO TS girls than in the whole TS cohort. With the HSDS rule, the AUC -value was 0.98 
(95% CI 0.97–1.00) in 45,XO TS girls and 0.97 (0.96–0.99) in all TS girls, and with the TH SDS 
rule, 0.99 (0.99–1.00) and 0.98 (0.96–0.99), respectively (Figure 22). In contrast, the screening 
accuracy with the 'HSDS  rule was slightly better for all TS girls than for 45,XO girls with 
AUCs of 0.72 (0.68–0.76) versus 0.71 (0.66–0.77). 'HSDS rule displayed a poorer screening 
accuracy than the HSDS or TH SDS rule alone. Combining the three rules resulted in an 
excellent screening accuracy with AUCs of 1.00 (0.99–1.00) for 45,XO TS girls and 0.99 (0.98–
1.00) for all TS girls, respectively. 
The OCP for HSDS rule was observed at -1.92 SDS with the sensitivity of 93% and 
specificity 93% in whole TS group, and -2.13 SDS with the sensitivity of 95% and specificity 
of 96% in the 45,XO group. The OCPs values for the TH SDS-rule and the 'HSDS rule were 
-2.03 (sensitivity-specificity pair 92%, 94%) and -0.40 (96%, 32%) for all, and -2.65 (98%, 
94%) and -0.40 (97%, 32%) for 45,XO TS girls, respectively. When the combination rule was 
used, OCP (HSDS-rule -2.43, THSDS-rule -1.60 and 'HSDS rule -1.44) was observed at 
sensitivity-specificity pairs 97%, 96% for all and 100%, 95% for 45,XO the TS girls. 
At all ages, the combination rule provided the highest sensitivity for all TS girls and also 
for the subgroup of 45,XO girls (Figure 23). By using the combination rule, 85% of all and 
93% of 45,XO TS girls were detected by the age of 2 years with 97% specificity, and 68% of 
all and 76% of 45,XO TS girls with 99% specificity, respectively. Additionally, all the 45,XO 
girls were detected by the age of 7 years with 97% specificity, and 97% of 45,XO girls by the 
age of 12 years with 99% specificity.  
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Figure 22. Receiver operating characteristics curves for the three growth screening rules (A–C) 
and their combination (D) in the TS population (n = 124, solid lines) and in a subsample of TS 
girls with karyotype 45,XO (n = 60, dashed lines): A, absolute HSDS rule; B, TH SDS rule; C, 
Ʃ+6'6UXOH'FRPELQDWLRQRIWKHVHWKUHHUXOHV+6'67+6'6RUƩ+6'6'Area under 
ROC-curve is shown separately for every rule. 
 
 
 
48
49 
 
 
Figure 23. Cumulative sensitivities of four growth screening rules from 0–12 years: HSDS rule, 
7+6'6Ʃ+6'6DQGFRPELQDWLRQRIWKHVHthree in the whole Turner syndrome (TS) group (A 
and B) (n = 124) and in the subsample of TS girls with karyotype 45,XO (C and D) (n = 60) at 
specificity levels of 97 and 99%, respectively. 
To some extent, all three screening rules complemented each other, as some of the girls 
were detected by a single rule only. The first alert was triggered by the HSDS rule in 20%, 
¢ȱȱ
ȱȱȱȱŘŚƖǰȱȱ¢ȱȱǊ
ȱȱȱŗŚƖȱȱȱȱǰȱ¢ǯȱ ȱ
or three rules were triggered in 42% of TS girls at the same time. In other words, removing 
any of the three rules from the combination resulted in lower sensitivity than could be 
achieved by the combination of the three rules. However, the 'HSDS rule did not improve 
the screening performance as much as the HSDS and TH SDS rules alone. 
Cumulative sensitivities of the HSDS, TH SDS rules and the combination of the three 
rules increased until 12 years of age, whereas with the 'HSDS rule, the highest sensitivity 
was obtained already by the age of 5 years. 
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5.3.2 Celiac disease 
Screening for abnormal growth in CD patients with any single screening parameter 
resulted in only poor to moderate accuracy (Figure 24). The single best screening parameter 
 ȱ̇HSDS in girls (AUC = 0.71; 95% CI 0.67 – ŖǯŝŝǼȱȱ̇ȱȱȱ¢ȱǻȱƽȱŖǯŝŘǲȱ
0.64 – 0.80). AUCs for HSDS, BMI SDS and TH SDS varied between 0.60 to 0.68 in girls and 
0.64 to 0.67 in boys, respectively. The five screening parameters when combined together 
(the combination rule, i.e. one or more abnormal screening parameters in a child) 
performed better than any of the parameters alone. AUC for the combination rule was 0.88 
(CI 0.84–0.93) in girls and 0.84 (CI 0.77–0.91) in boys.  
The accuracy of each of the growth screening parameters separately and the combination 
rule for detecting abnormal growth 5 years prior to the diagnosis of CD at 90, 95, and 99% 
specificity levels are presented in Table 10. Altogether, the sensitivity of the combination 
rule was 69% for girls and 61% for boys at 90% specificity. The corresponding sensitivities 
were 49% and 51% with 95% specificity for girls and boys, and 26% for both sexes with 99% 
specificity, respectively. With the respect to the separate growth screening parameters, the 
best results were obtained with HSDS and the distance from TH (TH SDS) for girls and BMI 
SDS for boys. 
In the analysis of the growth data of the 5 years before the CD diagnosis, the cumulative 
prevalence of an abnormal screening result using the combination rule increased the as one 
came closer to the diagnosis of CD (Figure 25). If the specificity level of the growth 
screening was set at 90% (i.e. 10% of children with abnormal screening result would not 
have CD), cumulative percentage of children with abnormal growth prior to or at CD 
diagnosis was 82% and 70% for girls and boys, respectively. The corresponding percentages 
at specificity levels 95% and 99% were 66% and 39% in girls, and 65% and 39% in boys. 
Abnormal growth was seen already two years prior to the CD diagnosis in 57% of the girls 
and in 48% of the boys (at the specificity level of 90%). The median delay between the first 
abnormal result by any of the growth screening rules and the CD diagnosis was 3.2 years in 
girls, and 2.7 years in boys at specificity level of 90%. If the specificity of the screening was 
set at 95 or 99%, the median delay was 3.0 or 2.6 years in girls, and 2.3 and 2.2 years in boys, 
respectively. 
 
 
 
 
Table 10. Sensitivity of each of the growth screening parameter and the combination rule in 
detecting abnormal growth in 177 celiac disease patients (106 girls, 71 boys) 5 years prior to 
diagnosis at 90, 95, and 99% specificity levels.  
 Specificity 90% Specificity 95% Specificity 99% 
Screening rule Girls Boys Girls Boys Girls Boys 
HSDS 31 (23-41) 25 (16-37) 24 (16-33) 15 (8-26) 10 (5-17) 6 (2-14) 
THSDS 31 (20-43) 26 (15-41) 23 (14-35) 16 (7-30) 11 (4-21) 2 (0-11) 
BMISDS 23 (15-32) 22 (13-35) 14 (8-23) 15 (8-26) 7 (3-14) 5 (1-13) 
Ʃ+6'6 31 (22-41) 27 (17-40) 20 )13-29) 17 (9-29) 10 (5-18) 8 (3-18) 
Ʃ%0,6'6 24 (16-35) 41 (28-56) 13 (7-22) 24 (13-38) 7 (2-14) 10 (3-22) 
Combination 69 (56-80) 61 (45-77) 49 (36-62) 51 (35-68) 26 (16-39) 26 (13-42) 
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Figure 24. Receiver Operating Characteristic (ROC) curves for the performance of five growth 
screening parameters and their combination in 106 girls (solid lines) and 71 boys (dashed lines) 
with celiac disease: Height and body mass index standard deviation score distance from the 
population mean (HSDS and BMI SDS parameters; panels A and B), HSDS distance from target 
KHLJKW 7+ 6'6 SDQHO & FKDQJH LQ %0, 6'6 DQG+6'6 RYHU WLPH ¨%0, 6'6 DQG Ʃ+6'6
parameters; panels D and E), and the combination of these five parameters panel F). The area 
under the curves (AUC) with 95% confidence intervals are shown. 
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Figure 25. Cumulative percentage of children with abnormal growth five years prior to the 
diagnosis of celiac disease. Abnormal growth is defined by “an alert triggered by any of the five 
growth screening parameters”, i.e. their use in combination, and specificity levels of 90%, 95%, 
and 99% in 106 girls (A) and 71 boys (B) are shown. Growth screening parameters are detailed 
in the text. 
5.4 AUTOMATED GROWTH MONITORING PROGRAM 
During the AM intervention year, 209 of 32,404 (0.64%) measured children were referred to 
secondary care for a suspected growth disorder. This was significantly more than in the 
previous control year, when only 68 of 32,718 (0.21%) measured children were referred 
onwards (RR for referral 3.10, 95% CI 2.36 to 4.08) (Figure 26).  
In the control year, 8 of the 68 referred children (11.8%) were diagnosed with a growth 
disorder: 4 had a primary or secondary growth disorder (detailed in Figure 26) and 4 had a 
diagnosis of ISS (after exclusion of other causes of short stature). The number of new 
diagnoses was significantly higher during the AM intervention year: altogether 48 children 
of the referred 209 children (23.0%) were diagnosed either with a primary or secondary 
growth disorder (n = 29) or ISS (n = 19) (detailed in Figure 26). RR for diagnosis of a 
primary or secondary growth disorder in the AM year was 7.57 (2.57 to 20.82) and if ISS 
was included, 6.06 (2.87 to 12.80). Alternatively, the RR for being healthy and being referred 
for a suspected abnormal growth during the AM year was 0.87 (0.78 to 0.98) in comparison 
to the control year. The diagnostic yield was one growth disorder for every 4090 
measurements during the control year, and in one growth disorder for every 675 
measurements during the AM intervention year.  
All eight children diagnosed with a growth disorder during the control year, and 42 of 
48 children (87.5%) during the AM intervention year had an abnormal growth screening 
result at referral (p = n.s., Fisher’s exact test).  Twenty-four of the 48 (50.0%) children 
diagnosed with a growth disorder during the AM year had had abnormal growth screening 
before the AM intervention year as assessed with standard monitoring, but these children 
were not referred to secondary care, which resulted in a delay in the diagnosis (Table 11). 
The median delay was 1.97 years (range 0.08 to 10.26 years).  
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6 Discussion 
6.1 GROWTH REFERENCES 
New length/height-for-age, weight-for-length/height, and BMI-for-age growth curves were 
developed to assess the growth of children in Finland. The advantages of these curves are 
that they include a large, contemporary population-based sample of healthy subjects; there 
was careful and prospective screenings and exclusion of subjects with potentially faltering 
growth; up-to-date statistical methods in curve construction; correction of a substantial 
secular change in the stature of Finnish children; and validation of the constructed BMI-for-
age curves against the international standard. It was found that misclassification of the 
height of contemporary Finnish children is common when using the previous height 
reference based on subjects born between 1959 and 1971 which further supported the need 
for an updated growth reference. These curves applicable across the population should be 
immediately implemented to monitor the growth of children and adolescents in Finland. 
The Finnish social security and primary healthcare systems provide free, regular check-
ups performed by well-trained nurses with standardized methods during the growth 
period (144). These visits are available to all permanent residents of Finland regardless of 
social status or income level; therefore, virtually every child is included. As a result, it is 
possible to perform population-based growth studies in a primary healthcare setting, such 
as the present one. Genetically, the inhabitants of the city of Espoo mirror that of the whole 
of Finland. The population of this city has grown by 10-fold over the past 60 years due to 
net migration from other parts of the country (152). The proportion of immigrants in Espoo 
was slightly higher than in the whole of Finland (7% vs. 4%); however, this proportion is 
continuously changing in other parts of the country as well.  
The initial database included the growth data of the entire child population, however, a 
series of exclusions were made to construct height curves that reflected optimal, healthy 
linear growth. Cleaning procedures followed the widely accepted methods described for 
example by the authors of the WHO growth standard study (20,156). Therefore, careful 
database cleaning was conducted to remove factors possibly influencing linear growth such 
as prematurity, low birth weight, childhood underweight, and obesity. Furthermore, 
special attention was paid to excluding children with any disorder or medication 
considered to possibly affect linear growth. Subsequently, the past and present growth data 
of each subject visiting either a child health clinic or school health care during the period of 
one year was assessed systematically according to a specific set of growth screening rules 
(3,4). Violation of the screening rules resulted in a visual inspection by a pediatric 
endocrinologist. As a result of these processes, it is believed that the length/height-for-age 
curves are an estimate of optimal growth. 
Optimal weight gain for children and adolescents is much more difficult to define than 
optimal linear growth. Weight gain is dependent on age and even more strongly on an 
increase in height, but only very poor or very excessive weight gain is associated with 
morbidity. Therefore, the original dataset for weight-for-length/height and BMI-for-age 
references was not cleaned as extensively. Only children with chronic diseases and 
medications affecting growth were excluded.  
For curve construction, the GAMLSS method was chosen; this is the same method 
recommended for mixed cross-sectional and longitudinal data by the WHO Multicentre 
Growth Study Group (156). 
It was found that secular changes in linear growth exhibited age- and sex-specific 
features. The growth in length of the height reference 1983–2008 population was more 
rapid in infants from birth to 5 months of age as compared to the reference 1959–71 
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population. The difference in height was up to 0.5 (girls) and 0.6 (boys) SDS between the 
reference 1983–2008 and reference 1959–71 populations by the age of 1 month. The change 
in infant feeding regimen may explain this difference. Currently, about 60% of infants are 
breastfed for at least for 6 months (157), whereas breastfeeding was relatively uncommon 
(5% for 6 months) for infants in the reference 1959–71 population (158). It is known that 
predominantly breastfed infants grow faster than formula-fed infants during their first 
months of life. Prolonged exclusive breastfeeding will, however, attenuate linear growth 
after three months of age (159). Indeed, infants in the reference 1983–2008 population grew 
at a much lower rate than infants in the reference 1959–71 population between the ages of 3 
and 6 months. Some of the differences in height in infancy may also be due to the different 
statistical methods used in the construction of the two reference periods.  
From about the age of 1 year up to 11.5 years in girls and 13 years in boys, there was a 
steady increase in mean height of the children in the reference 1983–2008 population as 
compared to the reference 1959–71 population. Boys of the new growth reference were on 
average up to 5.6 cm (0.70 SDS) taller than in the old reference between the ages of 12 and 
13 years. At all ages, secular increases in height were more marked in boys than in girls. In 
Finland, overweight is currently much more common in boys than in girls (112,113), 
suggesting that excessive energy gain is one factor resulting in the increased growth rate of 
boys. 
Data on pubertal stages were not included in this sample, but secular increases in height 
appeared to be linked to earlier maturation and earlier timing of the pubertal growth spurt 
compared to the reference 1959–71 population as evidenced by the greater increase in 
height during childhood than during adulthood. An earlier timing of puberty and has been 
recently described in Danish girls and boys (70,160). In Danish children, the early puberty 
was associated with higher BMI before the onset of puberty (70,160); however, there was a 
downward trend in the age at which puberty was attained in both girls and boys, 
regardless of the BMI, that suggests that the obesity epidemic is not solely responsible for 
the trend. 
Recent growth studies have claimed that the secular increases in adult height are 
gradually leveling off in several Northern European countries (10). In Finnish children, 
however, a marked increase was observed in adult height of 1.9 cm in girls and 1.8 cm in 
boys. The general belief is that the secular increase in height continues until the genetic 
potential of the population is reached. However, the current knowledge of the genetics of 
stature is insufficient to make an estimation of height potential of a population. 
Growth curves are used for screening of growth-related disorders, and a secular trend in 
linear growth has a direct influence on this process. One important fact of this study was 
the demonstration of how outdated cut-off-points could lead to a misclassification of 
children. Theoretically, an uncorrected secular trend of +0.4 SDS in mean height without a 
change in SD for height would mean that only 0.8% of children remained below the lower -
2 SDS limit and as many as 5.5% were above the upper +2 SDS limit, instead of the expected 
2.3% at both ends. These observations were consistent with such a rate of misclassification 
by the mean ±2 SD limits. Incorrect cut-off points at ±2 SD by 0.4 SDS would results in a 
3.4% reduction in specificity and up to a 32.6% reduction in sensitivity of screening of short 
and tall stature, which is unacceptable.  
Monitoring of weight is important in the detection of nutritional changes such as risk of 
malnutrition or obesity, or of chronic diseases affecting weight. Weight reference curves 
should include the definition of a normal weight range between thinness and overweight. 
In adults, one can use BMI cut-off points that have been agreed upon internationally: 
underweight BMI is <18.5 kg/m2); normal weight BMI is 18.5–24.9 kg/m2; overweight BMI 
is 25.0–29.9 kg/m2; and obesity BMI is >30 kg/m2 (135). It is important to remember that in 
children, body composition varies at according to age; therefore, factors affecting weight 
include not only height and sex, but also, to some extent, age of the child. Furthermore, 
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body composition and build also differ between populations (119). Thus, BMI reference 
curves need to be adjusted at least for sex and age and possibly, also for ethnicity. 
Initially, BMI-for-age percentile curves were constructed for children older than 2 years. 
Then, by using a widespread method devised by Cole, which uses BMI-for-age percentiles 
passing through various adult BMI cut-offs, it was possible to calculate BMI percentiles to 
define various grade of thinness, overweight, and obesity for Finnish children (135,136). 
The prevalence of grade 1 thinness (percentile passing through a BMI of 18.5 at the age of 
18 years) in the present sample was as high as 12.1% for girls and 17.9% for boys. As it 
would be both impractical and confusing to define such a high number of children and 
adolescents having grade 1 thinness, one can recommend using only grade 2 and grade 3 
thinness percentile curves (passing through BMIs of 17 and 16 at the age of 18 years, 
respectively).  
For Finnish boys, the prevalence of obesity was approximately the same as that recently 
reported by Vuorela et al. (4.4 % vs. 3.2%), but for girls, the prevalence was about half in the 
present sample (1.8% vs. 4.7%) (113). These results are not directly comparable, however, 
because here used BMI percentiles specific for Finnish children were used while the IOTF 
cut-offs were used in the other study. 
In comparison to weight-for-length/height, BMI-for-age has the advantage of being able 
to capture the changes in the weight-length/height relation with age and thus it is a 
measure that can be used continuously up to adulthood, as well as compared 
internationally. However, due to significant changes in BMI-for-age during the age of 0 to 2 
years, i.e. first the rapid increase and then the reduction; it is still recommended to use 
weight-for-length/height in that age group instead of BMI-for-age. The use of weight-for-
length/height has been criticized for several reasons. As reported by Cole (161), it is not 
independent on age, and therefore, it should be used only over a narrow age range. 
Furthermore, there are no cut-off values using weight-for-length/height to define 
underweight and obesity. Therefore, for older children the use of BMI-for-age rather than 
weight-for-length/height seems generally to be more advisable.  For the screening of obesity 
in children and adolescents, the United States Preventive Services Task Force recommends 
the use of BMI-for-age beginning at 6 years of age (162).  
The new Finnish growth references for length/height-for-age, weight-for-length/height 
and BMI-for-age created in this study using a contemporary, large Finnish population-
based sample are now available for primary healthcare providers and clinicians for 
updated growth monitoring. There are several advantages in replacing the growth curves 
currently in use by these updated and new references. The use of these new references 
should result in fewer misclassifications of normal growth in children thereby preventing 
unnecessary examinations in children with suspected growth failure. 
6.2 NATIONAL VERSUS MULTI-ETHNIC GROWTH REFERENCES 
AH varies significantly among populations, and is strongly genetically determined with 
heritability estimates of around 80% (80). Therefore, the childhood linear growth patterns 
are probably not as strongly determined as the weight by the optimal nutritional, 
environmental and psychosocial factors. In this respect the original assumption of uniform 
growth among populations may be incorrect and even affect adversely the screening of 
growth disorders.  
Height assessment in children growing at the outer percentiles with potential morbidity 
may be flawed if one uses the WHO standards. This thesis is, thought to be, the first to 
report the suboptimal accuracy of screening of a height disorder with the WHO standard in 
comparison to a population specific reference. Furthermore, Finnish children are on 
average 0.2-0.8 SDS taller than the WHO standard’s (I,20). In a recent study from Norway 
and Belgium, the proportions of the healthy children outside the ±2 SDS of WHO standards 
were different than expected (15). Thus the concept of “similarity” of heights among 
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children from different ethnic backgrounds under optimal conditions is questionable due to 
the fact that genetic differences have an impact on linear growth.  
Further studies in other populations and with other growth disorders are warranted. 
Before implementing the WHO growth charts in height screening, their performance 
should ideally be tested in the population for whom they are intended for. 
6.3 GROWTH MONITORING CUT-OFF VALUES FOR ABNORMAL GROWTH 
Growth monitoring is a fundamental part of primary healthcare in children, but the 
performance of various growth monitoring parameters in the context of screening program 
has remained inadequately explored. A recent systematic review on growth monitoring for 
short stature claimed that optimal cut-off points for abnormal growth are virtually absent 
(1). One major strength of the present study was the establishment of population-based 
screening cut-off values for abnormal growth, which were developed using a large, 
contemporary height data set of healthy children.  
This study represented an extensive methodological exercise to optimize auxological 
screening of abnormal growth. First, age-specific normal values were calculated for the 
height distance from TH. The data showed that height distance from TH in a population 
was age-dependent and should be taken into account in growth monitoring. Second, a 
method was developed based on the change in height SDS and BMI SDS to assess changes 
in growth rate over time between age points from 0 to 12 years. As far as is known, this is 
the first study to define population-based, age-specific reference values for height SDS 
distance from the TH SDS, as well as limits for the changes in growth rate that are scalable 
freely between any two age points. Ultimately, these new population-based auxological 
screening cut-off values were validated for height SDS, BMI SDS, height distance from TH 
SDS and changes in growth rate (height SDS and BMI SDS) in a retrospective clinical 
datasets of 124 girls with TS, and 106 girls and 71 boys with CD, respectively.  
6.4 AUXOLOGICAL SCREENING ACCURACY FOR TURNER SYNDROME   
In this study TS was used as a model disorder because of the fact that short stature is often 
the only or at least the most obvious clinical sign. By using three growth monitoring 
parameters for height (height SDS, TH SDS and 'HSDS), it was possible to detect abnormal 
growth in TS with excellent accuracy already at a young age. However, growth monitoring 
programs aim at identifying not only TS but a variety of other disorders affecting growth. 
Grote et al. (29) have shown that the growth patterns of the most prevalent growth 
disorders (TS, GHD, CD and cystic fibrosis) vary by age and the screening rule to be used, 
but overall TS appears to be an optimal target group for screening. However, further 
studies in clinical disorders other than TS are still warranted. 
An ideal growth monitoring program should have a high sensitivity in order to detect as 
many abnormally growing children as possible, with the kind of specificity that does not 
produce too many unnecessary referrals. However, one always has to make a trade-off 
between sensitivity and specificity. For the height SDS cut-off (or height percentile cut-off) 
values, the specificity is pre-defined by the growth references without any knowledge of 
the sensitivity for each of the detectable growth disorders. In the previous study of van 
Buuren et al. (28) 70% of TS girls could be detected with the HSDS rule with a specificity of 
93%. In contrast, in this study it was possible to detect as many as 93% of TS girls with the 
same specificity by using the HSDS rule. The difference can be explained by two factors. 
The TS girls in the present cohort were born between 1978 and 2009, as were the majority of 
the children in the reference population (I) whereas in the Dutch study, TS girls were older 
than children in the reference data (born between 1968 and 1996 in comparison to reference 
girls born between 1989 and 1990). Furthermore, the reference children were on average 
0.31 SDS shorter than the Dutch reference population (28).  
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Height distance from TH, in comparison to height SDS, is believed to improve sensitivity 
without significantly reducing specificity, because the SD for TH is narrower than the SD 
for height (131). Several methods have been proposed for calculating TH(132-134). The 
present study, the TH SDS formula of Wright et al (132) was very accurate in predicting the 
adult height and was also consistent with height SDS in all age ranges in the population 
sample. 
 In the study of Van Buuren et al (28), height distance from TH in the screening for TS 
was assessed as well, although in their study, a large proportion of maternal or paternal 
heights were imputed due to missing data. Screening of TS with the TH rule in this study 
produced similar performance as that reported by Van Buuren et al (28). In another Dutch 
study reported by Grote et al. (29), it was found that the use of TH was superior to height 
SDS only in growth screening. Therefore, parental heights should be systematically 
recorded for each child and TH-based screening may then become useful, especially in 
multi-ethnic populations when population-specific growth references are not available. 
Gozzi et al. (163) reported that short parents tend to overestimate their height, and 
therefore actual measurement of parental heights if possible is preferable.  
The change in growth rate is virtually an unexplored approach in the screening of 
growth disorders, and population-based reference values to describe normal changes are 
virtually non-existent (3,4). One advantage in the method reported in this study is that the 
cut-off values for abnormal growth rate can be defined for any age range between 0 and 12 
years. Nevertheless, the £ȱȱ ȱȱǻ̇
ȱǼȱȱ¢ȱȱȱȱ
accuracy of height measurements.  
It does seem that almost 40% of growth disorders can be identified based on an 
abnormal growth rate before the child is abnormally short or tall (unpublished 
observation). In one previous study, the combination of height-for-age, height distance 
from TH and change in growth rate has been reported to detect children with short stature 
with good sensitivity and acceptably high specificity (29). The result in the screening of TS 
substantiates these findings, although TS is a growth disorder with a prenatal origin and 
thus the main growth feature is a short stature for age or abnormal distance of height from 
TH. Therefore, screening by using the changes in growth rate is probably more accurate in 
disorders that typically manifest via a decrease in height SDS or height percentile, e.g. 
GHD, hypothyroidism and CD.  
Growth in TS girls typically is affected already in utero and in infancy, but nonetheless 
in two previous studies only about one third of TS girls had been identified by mid-
childhood (83,84). The present results on cumulative sensitivity by age revealed that TS 
girls can be potentially detected much earlier, as many as 80% (specificity 99%) by the age 
of 5 years if one undertakes systematic population-based growth monitoring and by 
following the screening rules. Furthermore, karyotype should be examined for girls with 
typical clinical findings for TS (e.g. lymphedema at birth, webbed neck or cubitus valgus), 
especially if they are short. 
6.4 AUXOLOGICAL SCREENING ACCURACY FOR CELIAC DISEASE 
This study revealed that the majority of the children diagnosed with CD could have been 
detected by appropriate auxological screening. Most CD children developed growth failure 
prior to the diagnosis, and on average, CD children were shorter than the healthy reference 
population. Thus auxological screening would be a simple and non-invasive method to 
improve the early diagnosis of CD in children. The best results should be obtained by 
implementing a well-established longitudinal growth monitoring program, and systematic 
screening with contemporary cut-off values for both height and weight.  
The major strengths of this study was the use of a population-based, contemporary 
growth reference and cut-off values, including the change in height SDS and BMI SDS over 
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time, which enable assessment of subtle changes in the growth rate. Only a few previous 
studies have assessed the use of growth rate in screening (29).  
The weakness of this study was its retrospective nature and data collection from patient 
files, which did not include systematic notes on intestinal and extra-intestinal symptoms 
prior to the diagnosis of CD. However, it is believed that the retrospective growth data 
were not biased. Data were retrieved from electric health records, based on population 
based growth monitoring program which has been operative from the 1990s. All children 
the present CD cohort had been measured according to this program. The quality of growth 
data gathered at routine visits has also been assessed; false measurements, typing errors, 
missing values, or duplicate recordings are scarce (97).   
The clinical pattern of childhood CD has changed from the classical triad – failure to 
thrive, diarrhea and abdominal distention – to a large variety of nonspecific signs and 
symptoms (85-89), as shown also in the present cohort. Abnormal growth is the most 
common extra-intestinal symptom of CD (164). The probability of CD is estimated to range 
from 19 to 59% in children with short stature of a non-endocrinological cause (164-168). 
Nevertheless, severe growth failure is uncommon in children with CD today, particularly 
in the developed countries (164-168). Growth failure in contemporary CD children was not 
even seen in the study of Savilahti et al. (169), which is in contradiction with the present 
observations. This discrepancy was probably due to the fact that the growth failure is 
relatively subtle in its nature, and as they used outdated growth references in the 
evaluation of growth, the secular changes in height introduced a systemic error into their 
data. The present findings of impaired growth in CD patients are in agreement with the 
study of Korponay-Szabo et al (170). They performed a universal serological screening for 
CD among 6 year-old children in one county (n = 2360), and diagnosed altogether 32 new 
CD cases. These 32 children were on average shorter and lighter than their healthy peers 
(170).  
Consistent with the present results, in Dutch cohort van Dommelen et al. recently 
showed that a change in BMI SDS was the most accurate parameter to detect CD (171). 
However, the Dutch cohort was composed almost entirely of infants and small children (0 
to 2.5 years of age) whereas the children in the present study ranged in age from infancy to 
late puberty and therefore the two studies are not directly comparable. It was found that 
the best screening accuracy for CD was achieved by combining various growth screening 
parameters. Nevertheless, the screening accuracy for CD still remained inferior to some 
other disorders affecting growth, such as Turner syndrome (29). The diagnostic accuracy of 
any screening program is always a trade-off between sensitivity and specificity. Growth 
monitoring cut-offs are intended to detect as many abnormally growing children as 
possible (high sensitivity) without producing too many unnecessary referrals or further 
investigations (high specificity). In that respect, relatively low specificity can be considered 
as acceptable for CD, because detected children can be investigated further by a simple and 
cheap serological testing. 
Recent data have shown that CD remains severely underdiagnosed in the Western 
populations (86,90-92), and therefore new tools to improve diagnosis are needed. Universal 
population screening by serology is not currently advised. Growth monitoring is performed 
in almost every developed country. Improvements towards systematic growth screening by 
pre-established rules would facilitate more efficacious screening of disorders such as CD. 
This was shown also in the present study by a significant diagnostic delay between the first 
abnormal height or weight measurement and the diagnosis of CD. In addition, the use of 
population based growth reference instead of universal reference can facilitate the 
identification of subtle forms of growth failure, as shown previously in the context of 
Turner syndrome (II). It has been demonstrated here that implementation of a growth 
monitoring program into EHR and computerization of the screening is a feasible and 
effective method to improve the early diagnostics of growth disorders (V). Consequently, it 
was recommended that systematic growth screening is adopted as a primary method for 
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early detection of chronic disorders affecting growth, such as CD. A prospective 
population-based study is warranted to evaluate the benefits and costs of such a screening 
program. 
The weakness of the both studies, in girls with TS and in children with CD, was their 
retrospective nature and the collection of data from patient files. The best approach would 
be prospective population-based screening study in which growth screening parameters 
were compared to pre-defined examination in secondary healthcare (e.g. karyotype in girls 
with short stature) or serological screening tests for CD. However, growth monitoring is 
not intended to detect only one or two disorders affecting growth, but systematic growth 
monitoring program can improve the screening process of growth disorders in general 
(125).    
6.5 AUTOMATED GROWTH MONITORING PROGRAM 
This population-based cohort study demonstrated that automated growth monitoring 
implemented in the primary care EHR system can improve the effectiveness of growth 
screening in children. The AM strategy improved the detection rate of growth disorders by 
6-7-fold. It also identified numerous children with a growth disorder who were being 
previously missed by the standard growth monitoring.  
A major strength of this study was the use of a large unselected target population 
covered by well-organized primary care. The acceptance of the public growth screening 
during the AM year remained the same as in the control year and was almost 100% of the 
eligible population(172). In previous growth monitoring studies, the reported percentage of 
eligible children measured has ranged from 45 to 90% (29,32,137-148) Another strength of 
the present study was the wide array of growth conditions screened for, including primary 
and secondary disorders causing either short or tall stature. Only two of the 12 previous 
studies on growth monitoring programs (32,142) have focused on both short and tall 
stature, the others have concentrated on short stature only (29,139-141,143-148). The present 
data revealed that disorders causing excessive growth are also common among stature 
related disorders and should be included in monitoring strategies. In our study, the benefits 
of AM might have been exaggerated, because the majority of the child population, nearly 
90%, had also been screened in the preceding years using the standard monitoring. For the 
same reason, the diagnostic yield during the AM does not reflect the total prevalence of 
growth disorders in the population, but the incremental yield. One limitation of the study 
was that those assessed as healthy were not followed after the AM intervention. Thus, only 
false positive cases, and a subset of true positive cases were identified. 
This is thought to be the first study to assess the impact of an automated growth 
monitoring integrated into EHR in primary care. The German program described by Keller 
et al (32) is another computer-based monitoring system, in which routine height 
measurements is being gathered in more than 100 participating paediatric practices 
throughout a wide area of Germany. Children with heights above the 97th percentile or 
below the 3rd percentile on the German synthetic normal curve were highlighted to the 
relevant practice, and children were referred for specialist investigation if this was 
considered necessary. This program clearly produced the best overall diagnostic yield (one 
per 545) of all of the 12 previously published growth screening programme studies 
(29,32,139-148). The diagnostic yield in the present study during the AM intervention was 
close to that found in the Keller study (one per 675) (32). However, based on the prevalence 
of disorders potentially affecting linear growth, one can assume that even during the AM, a 
significant amount of pathological growth will remain undiagnosed but they may be 
detected in subsequent years. The significant amount of non-referrals during the standard 
monitoring led to delayed diagnoses. Automation of the screening rules during the AM led 
to recognition of all children with abnormal screening but the present referral rate only 
increased from 0.2% to 0.6%. This low referral rate can be explained by the online 
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consultation by a pediatric endocrinologist, as only 13% of the alarmed cases were 
ultimately referred to specialist care for further investigation. In addition, it reflects the fact 
that the screening rules are far from optimal, although their performance can be improved 
by automation. Even though most industrialized countries have growth monitoring 
programs for children, there is very little evidence-based data to determine the best 
screening rules for detecting abnormal growth (1,29). This area clearly warrants further 
studies.  
The present data support the idea that growth monitoring is an effective option in 
general and support the findings of Fayter at al. (137). Early diagnosis is an issue that will 
hugely affect the benefits of any growth monitoring programme. The issue of late versus 
early detection could not be fully addressed in the present model, because of the relatively 
small number of disorders diagnosed. However, it was demonstrated clearly that diagnoses 
could be made earlier with the AM than with the manually performed standard 
monitoring.  
Healthcare in the developed countries is entering a new era in which healthcare systems 
will be the key to delivering safe, effective, and efficient care. EHRs will play a central role 
in this transformation. EHRs can help clinicians to adhere to guideline-based care and 
reduce medication errors (173,174), but empirical data showing either quality improvement 
or cost savings from EHR adoption are scarce. This study reveals that the automation of 
several growth screening steps, using the EHR systems currently available, is a simple way 
to improve the detection of growth disorders in a general child population. Despite existing 
differences in growth monitoring programs internationally, it is likely that automation of 
growth screening will be also beneficial for other populations. It is conceivable that very 
complex screening algorithms could be incorporated into fully computerized monitoring 
programs to obtain reliable automated growth screening. However, some important issues, 
such as the optimum ages for screening and the evidence-based screening criteria still 
remain unresolved. 
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7 Conclusions 
In conclusion, an optimal growth monitoring program requires standardized equipment, 
well-trained nurses, an adequate population based reference and evidence-based screening 
rules and referral criteria approved by pediatric growth specialists.  
The new Finnish growth references for length/height-for-age, weight-for-length/height, 
and BMI-for-age created in this study using a contemporary, large, Finnish population-
based sample are now available for primary health care providers and clinicians to permit 
updated growth monitoring. There are several advantages in replacing the growth curves 
currently in use with these up-dated references. The adoption of these new references 
should result in fewer misclassifications of normal growth in children, thereby preventing 
unnecessary examinations in children with suspected growth failure. 
This is the first study to report the suboptimal accuracy of screening of a height disorder 
with the WHO standard in comparison with a population specific reference. Further studies 
in other populations and with other growth disorders are warranted. Before implementing 
the WHO growth charts in height screening, their performance should ideally be tested in 
the population in whom they are intended to be used. 
The establishment of population-based, validated cut-off values for height-for-age, 
height distance from TH and changes in growth rate would represent a crucial step towards 
evidence-based growth monitoring, and should be implemented in growth monitoring 
programs. The screening algorithms such as the cut-off values for growth rate are complex, 
and therefore their efficient use requires computerization.  
The integration of screening algorithms into contemporary electronic patient 
management systems could be an interesting way to screen for growth disorders in the 
future. Automation of several growth screening steps, using the EHR systems available, is a 
simple and cost effective way to improve the detection of growth disorders in a general 
child population. Despite existing differences in growth monitoring programs 
internationally, it is predicted that automation of growth screening will also be beneficial 
for other populations. It is conceivable that very complex screening algorithms could be 
included in fully computerized monitoring programs to help obtain reliable automated 
growth screening. However, some important issues, such as the optimum ages for 
screening and the evidence-based screening criteria still remain unresolved. 
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